EXTEMPORANEOUS MANUFACTURING OF INTRAVENOUS ADMIXTURES IN HOSPITAL PHARMACIES OF RUSSIAN FEDERATION


Cite item

Full Text

Abstract

The provision of patient-centered pharmaceutical care is carried out through pharmaceutical organizations and is accompanied by such necessary functions as counseling, provision of information on drugs, monitoring of drug therapy. It also includes ensuring quality, effective and safe drugs. In this case, the role of pharmacies is reduced to providing the population with ready-made products of industrial production. The problem of improving the technology of infusion solutions assigned in stationary conditions, including combined drugs of individual manufacture is especially acute.The aim of this work was to study and analyze the options for the extemporaneous manufacture of combined drugs for infusion introduction in hospital pharmacies.Materials and methods. The methodological basis of the study was a systemic approach, which makes it possible to identify the key elements of two different options for the extemporaneous manufacture of combined drugs for infusion administration. The research uses methods of logical and functional analyses.Results and discussion. The analysis of scientific sources on the issues of manufacturing of combined infusion solutions for the needs of stationary patients showed that manufacturing is carried out according to the traditional scheme for the Russian Federation, i.e. in the conditions of the procedural room of the department. In pharmacies of medical organizations, two variants of small-scale extemporal manufacture of combined infusion solutions are permissible using pharmaceutical substances and using sterile drugs of industrial production. The presence of a number of critical points of the first variant shows the irrationality and limitations of the use of such a scheme for the manufacture of combined infusion solutions in the pharmacy of a medical organization. The second version of the extemporal manufacture of combined infusion solutions is characterized by the simplicity of the technological scheme, the absence of complex calculations, a number of preparatory operations, filtration and sterilization steps, a simplified version of quality control, and the lack of complex equipment. This allows the rapid and large-scale production of various combinations of drugs for infusion.Conclusion. Manufacturing intravenous admixtures from commercial medicines allows the rapid and large production of various combinations of drugs for infusion introduction, does not contradict the current legislation, which makes it possible to consider it as the main variant of manufacturing of combined infusion solutions in hospital pharmacies.

Full Text

ɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬɟɯнолоɝияɛиоɬɟɯнолоɝияPharmaceutical Technology and BiotechnologyɍȾКˑКˁ˃ʫʺʿОˀʤЛːʻОʫʰʯʧО˃ОʦЛʫʻʰʫКОʺʥʰʻʰˀОʦʤʻʻˏˈʿˀʫʿʤˀʤ˃Оʦʰʻˇ˄ʯʰОʻʻОʧОʿˀОʰʯʦОʪˁ˃ʦʫʻʻˏˈОˀʧʤʻʰʯʤˉʰʱˀОˁˁʰʰКоɜɚльɫкɚяМиɯɚлɟɜичИɪкɭɬɫкɚяɝоɫɭɞɚɪɫɬɜɟннɚямɟɞицинɫкɚяɚкɚɞɟмияпоɫлɟɞипломноɝооɛɪɚзоɜɚнияɊоɫɫийɫкойɎȽȻɍɊоɫɫийɫкɚямɟɞицинɫкɚяɚкɚɞɟмияпɪоɮɟɫɫионɚльноɝооɛɪɚзоɜɚнияɫɬɜɚзɞɪɚɜооɯɪɚнɟнияɊоɫɫийɫкойɎɟɞɟɪɚцииɊоɫɫияЮɛилɟйныйОкɚзɚниɟɮɚɪмɚцɟɜɬичɟɫкойпомощиоɪиɟнɬиɪоɜɚннойпɚциɟнɬɚоɫɭщɟɫɬɜляɟɬɫячɟɪɟзɮɚɪмɚцɟɜɬичɟɫкиɟɫопɪоɜожɞɚɟɬɫяɬɚкиминɟоɛɯоɞимымиɮɭнкциямикɚкконɫɭльɬиɪоɜɚниɟпɪɟɞоɫɬɚɜлɟниɟинɮоɪмɚциилɟкɚɪɫɬɜɟннымпɪɟпɚɪɚɬɚмлɟкɚɪɫɬɜɟннойɬɚкжɟɜключɚɟɬоɛɟɫпɟчɟниɟкɚчɟɫɬɜɟннымиэɮɮɟкɬиɜнымиɛɟзопɚɫнымиэɬомɪольɫɜоɞиɬɫяоɛɟɫпɟчɟниюнɚɫɟлɟнияпɪомышлɟнноɝопɪоизɜоɞɫɬɜɚОɫоɛɟнноɜопɪоɫɜɟɪшɟнɫɬɜоɜɚнияɬɟɯнолоɝииинɮɭзионныɯɪɚɫɬɜоɪоɜнɚзнɚчɚɟмыɯɫɬɚционɚɪныɯɭɫлоɜияɯɬомчиɫлɟкомɛиниɪоɜɚнныɯинɞиɜиɞɭɚльноɝоизɝоɬоɜлɟнияЦɟльюиɫɫлɟɞоɜɚнияяɜилоɫьизɭчɟниɟɜɚɪиэкɫɬɟмпоɪɚльноɝоизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионноɝоɜɜɟɞɟнияпɪоизɜоɞɫɬɜɟнныɯɚпɬɟкɚɯмɟɞицинɫкиɯМɚɬɟɪиɚлымɟɬоɞыМɟɬоɞолоɝичɟɫкойоɫноɜойиɫɫлɟɞоɜɚнияɫɬɚлɫиɫɬɟмныйпоɞɯоɞпозɜоляющийɜыɞɟлиɬьключɟɜыɟэлɟмɟнɬыɞɜɭɯɪɚзличныɯɜɚɪиɚнɬоɜэкɫɬɟмпоɪɚльизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионноɝоɜɜɟɞɟнияиɫɫлɟɞоɜɚниииɫпользоɜɚнымɟɬоɞылоɝичɟɫкоɝоɮɭнкционɚльноɝоɊɟзɭльɬɚɬыоɛɫɭжɞɟниɟнɚɭчныɯиɫɬочникоɜɜопɪоɫɚмизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜнɭжɞɫɬɚционɚɪныɯпокɚзɚлизɝоɬоɜлɟниɟоɫɭщɟɫɬɜляɟɬɫяɊоɫɫийɫкойɎɟɞɟɪɚцииɫɯɟмɟ ? ɭɫлоɜияɯпɪоцɟɞɭɪноɝокɚɛинɟɬɚоɬɞɟлɟнияɚпɬɟкɚɯмɟɞицинɫкиɯɞɜɚɜɚɪиɚнɬɚмɟлкоɫɟɪийноɝоэкɫɬɟмпоɪɚльноɝоизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜиɫпользоɜɚниɟмɮɚɪмɚцɟɜɬичɟɫкиɯɫɭɛɫɬɚнцийиɫпользоɜɚниɟмпɪомышлɟнноɝопɪоизɜоɞɫɬɜɚцɟлоɝоɪяɞɚкɪиɬичɟɫкиɯɬочɟкпɟɪɜоɝоɜɚɪиɚнɬɚпокɚзыɜɚɟɬиɫпользоɜɚнияпоɞоɛнойɫɯɟмыизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜɭɫлоɜияɯмɟɞицинɫкойȼɬоɪойɜɚɪиɚнɬэкɫɬɟмпоɪɚльноɝоизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜоɬличɚɟɬɬɟɯнолоɝичɟɫкойɫɯɟмыоɬɫɭɬɫɬɜиɟмɫложныɯɪɚɫчɟɬоɜɪяɞɚпоɞɝоɬоɜиɬɟльныɯɫɬɚɞийɮильɬɪɚцииɭпɪощɟннымɜɚɪиɚнɬомконɬɪолякɚчɟɫɬɜɚоɬɫɭɬɫɬɜиɟмɫложноɝооɛоɪɭɞоɜɚнияЗɚключɟниɟИзɝоɬоɜлɟниɟкомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜпɪомышлɟнноɝопɪоизɜоɞɫɬɜɚпозɜоляɟɬɛольшиɯколичɟɫɬɜɚɯизɝоɬɚɜлиɜɚɬьɪɚзличныɟкомɛинɚцииинɮɭзионноɝоɜɜɟɞɟнияпɪоɬиɜоɪɟчиɬɞɟйɫɬɜɭющɟмɭзɚконоɞɚɬɟльɫɬɜɭɞɚɟɬɜозможноɫɬьɫмɚɬɪиɜɚɬькɚчɟɫɬɜɟɜɚɪиɚнɬɚизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜɚпɬɟкɚɯмɟɞицинɫкиɯКлючɟɜыɟɫлоɜɚкомɛиниɪоɜɚнныɟлɟкɚɪɫɬɜɟнныɟинɮɭзионноɝоɜɜɟɞɟнияэкɫɬɟмпоизɝоɬоɜлɟниɟмɟɞицинɫкиɟциɬиɪоɜɚнияКоɜɚльɫкɚяМиɯɚлɟɜичЭКɋɌȿМПОɊȺЛЬНОȿИЗȽОɌОȼЛȿНИȿКОМȻИНИɊОȼȺННЫɏЛȿКȺɊɋɌȼȿННЫɏПɊȿПȺɊȺɌОȼИНɎɍЗИОННОȽОПɊОИЗȼОȾɋɌȼȿНОɊȽȺНИЗȺЦИЙɊОɋɋИИɎɚɪмɚцияɮɚɪмɚколоɝияКоɜɚльɫкɚяМиɯɚлɟɜичFor citation:EXTEMPORANEOUS MANUFACTURING OF INTRAVENOUS ADMIXTURES IN HOSPITAL PHARMACIES OF RUSSIAN FEDERATION. Pharmacy & Pharmacology. 2017;5(4):306-317. (In Russ.) Pharmacy & Pharmacology V. 5 N 4, 2017ȼɜɟɞɟниɟМɟɞицинɫкɚяпомощьокɚзыɜɚɟмɚяпɚциɟнɬɚмɫɬɚционɚɪныɯɯɚɪɚкɬɟɪизɭɟɬиɫпользоɜɚниɟмлɟкɚɪɫɬɜɟнныɯɬоɜинɮɭзионноɝоɜɜɟɞɟниякɚккɚчɟɫɬɜɟмоноɬɟɪɚпииɬɚкɮоɪмɚɬɟкомɛиниɪоɜɚнноймɚкоɬɟɪɚпии [1]. оɞноɜɪɟмɟнноɝонɚзнɚчɟɞɜɭɯɛолɟɟоɞнойинɮɭзииɜозникɚɟɬпɪоɫкɚчɟɫɬɜɚкомɛинɚции [2, 3]. Эɬоɫɜязɚноɬɪɚɞиционнымизɝоɬоɜлɟниɟмкомɛиниɪоɜɚнныɯпɪопиɫɟймɟɞицинɫкимиɫɟɫɬɪɚминɟпоɫɪɟɞɫɬɜɟннооɬɞɟлɟниячɬооɬɫɭɬɚнɚлизɚнɚзнɚчɟнияɫоɜмɟɫɬимоɫɬькомпонɟнɬоɜоɬɫɭɬɫɬɜиɟконɬɪолякɚчɟɫɬɜɚɞолжныɯɝоɬоɜыɯɬɜоɪоɜпозɜоляɟɬоɛɟɫпɟчиɬькɚчɟɫɬɜоэɮɮɟкɬиɜноɫɬьɛɟзопɚɫноɫɬьɮɚɪмɚкоɬɟɪɚпии [2, 3]. Нɚ ɫɟɝоɞняшниймɟɞицинɫкиɯокɚзыɜɚющиɯпомощьɫɬɚционɚɪныɯɬɪɚɞиционнымɫчиɬɚɟɬɫяизɝоɬоɜлɟниɟкомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜɫɪɟɞниммɟɞицинɫкимпɟɪɫонɚломпɪоцɟɞɭɪноɝокɚɛинɟɬɚɬочкиɮɚɪмɚцɟɜɬичɟɫкойɬɟɯнокɚжɞыйэɬɚппоɞоɛнойɫɯɟмыяɜляɟɬɫянɟкоɪɪɟкɬнымнɚличияцɟлоɝокɪиɬичɟɫкиɯɪɚмɟɬɪоɜпɪоɛлɟмойэɬоɝоэɬɚпɚяɜляɟɬɫяоɬɫɭɬноɪмɚɬиɜныɯɞокɭмɟнɬоɜɪɟɝлɚмɟнɬиɪɭющиɯизɝоɬоɜлɟниɟкомɛиниɪоɜɚнныɯинɮɭзионныɯɬɜоɪоɜОɬɟчɟɫɬɜɟнныɟɪɭкоɜоɞɫɬɜɚɫɟɫɬɪинɫкиммɚнипɭляциямɜключɚюɬнɟпоɫɪɟɞɫɬɜɟнноɬɟɯникɭɜɜɟɞɟниякомɛиниɪоɜɚнноɝоинɮɭзионноɝоɪɚɫɬɜоɪɚоɞнɚкопɪоцɟɫɫɟɝоизɝоɬоɜлɟнияпɪопиɫыɜɚɟɬɫяɫɭɬиизɝоɬоɜлɟниɟкомɛиниɪоɜɚнныɯинɮɭɪɚɫɬɜоɪоɜ ? эɬоɫмɟшиɜɚниɟкɚɪɫɬɜɟнныɯɮоɪмоɞномɮлɚконɟконɬɟйнɟɪɟпоɞоɛныɟпопɚɞɚлипоɞопɪɟɞɟлɟниɟɎɟɞɟɪɚльноɝозɚконɚ 22 1998 кɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜɚɯкоɬоɪоɟɝлɚɫилоИзɝоɬоɜɚпɬɟчномɜключɚɟɬɜɫɟпɪиɝоɬоɜлɟнияпɟɪɟлиɜɚниялɟкɚɪɫɬɜɟнɮоɪмɪɚзлиɜɚниɟɟмкоɫɬямоɬноɫиɬɫяɮɚɪмɚцɟɜɬичɟɫкойɞɟяɬɟльноɫɬиȾɟйɫɬɜɭющийнɚɫɬоящɟɟɎɟɞɟɪɚльныйзɚкон 12.04.2010 лɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜɞɪɭɝиɟноɪмɚɬиɜнопɪɚɜоɜыɟɚкɬыɫожɚлɟниюɎɟɞɟɪɚльныйзɚкон 61-ɞɚюɬчɟɬкоɝоEXTEMPORANEOUS MANUFACTURING OF INTRAVENOUS ADMIXTURES IN HOSPITAL PHARMACIES OF RUSSIAN FEDERATIONIrkutsk State Medical Academy of Postgraduate Education ? a branch of the Russian Medical Academy of Continuing Vocational Education, 100, Yubileiny, Irkutsk city, Russia, 664079The provision of patient-centered pharmaceutical care is carried out through pharmaceutical organizations and is accompanied by such necessary functions as counseling, provision of information on drugs, monitoring of drug therapy. It also includes ensuring quality, effective and safe drugs. In this case, the role of pharmacies is reduced to providing the population with ready-made products of industrial production. The problem of improving the technol-ogy of infusion solutions assigned in stationary conditions, including combined drugs of individual manufacture is of this work was to study and analyze the options for the extemporaneous manufacture of combined drugs for infusion introduction in hospital pharmacies. The methodological basis of the study was a systemic approach, which makes it possible to identify the key elements of two different options for the extemporaneous manufacture of combined drugs for infusion administration. The research uses methods of logical c sources on the issues of manufacturing of combined infusion solutions for the needs of stationary patients showed that manufacturing is carried out according to the traditional scheme for the Russian Federation, i.e. in the conditions of the procedural room of the department. In pharmacies of medical organizations, two variants of small-scale extemporal manufacture of combined infusion solutions are permissible - using pharmaceutical substances and using sterile drugs of industrial production. The presence of a number of critical points of the rst variant shows the irrationality and limitations of the use of such a scheme for the manufacture of combined infusion solutions in the pharmacy of a medical organization. The second version of the extemporal manufacture of combined infusion solutions is characterized by the simplicity of the techno-logical scheme, the absence of complex calculations, a number of preparatory operations, ltration and sterilization ed version of quality control, and the lack of complex equipment. This allows the rapid and large-scale production of various combinations of drugs for infusion. Manufacturing intravenous admixtures from commercial medicines allows the rapid and large pro-duction of various combinations of drugs for infusion introduction, does not contradict the current legislation, which makes it possible to consider it as the main variant of manufacturing of combined infusion solutions in hospital phar-: combined medications for infusion, extemporaneous manufacturing, medical organizationsɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬɟɯнолоɝияɛиоɬɟɯнолоɝияPharmaceutical Technology and BiotechnologyопɪɟɞɟлɟнияизɝоɬоɜлɟниɟɌɟмɬɟɪминизɝоɬоɜлɟниɟоɬноɫиɬɫямɚцɟɜɬичɟɫкойɞɟяɬɟльноɫɬиɭпоминɚɟɬɫяɬолькоɬɟɯɪɚзɞɟлɚɯкоɬоɪыɟнɟпоɫɪɟɞɫɬɜɟнноɝлɚмɟнɬиɪɭюɬechnology and Biotechnologyȼ ɬо жɟ ɜɪɟмя, зɚ ɪɭɛɟжомчɚɫɬноɫɬиɫɬɪɚнɚɯȺɜɫɬɪɚлиипɪоɛлɟмɚизɝоɬоɜлɟниякɚчɟɫɬɜɟнныɯкомɛиниɪоɜɚнныɯинɮɭɪɚɫɬɜоɪоɜɪɟшɚɟɬɫяпɟɪɟɞɚчиполномочийэкɫɬɟмпоɪɚльномɭизɝоɬоɜлɟниюɫɪɟɞɫɬɜɟнноɚпɬɟкимɟɞицинɫкиɯ [7]. ɮɚɪмɚцɟɜɬичɟɫкиɟɫпɟциɚлиɫɬыɪɚɛоɬɚющиɟмɟɞицинɫкиɯокɚзыɜɚющиɟпомощьпɚциɟнɬɚмɫɬɚционɚɪныɯɬɚкжɟɜнɟɫɬизнɚчиɬɟльныйɜɟɞɟниɟнɚльнойɮɚɪмɚкоɬɟɪɚпииɫоɜмɟɫɬномɟɞицинɫкимиɫпɟциɚлиɫɬɚмиɫɟɝоɞняшнийɫɬɚционɚɪнымɬɚммɟɞицинɫкиɯнɚзнɚчɚɟɬɫяɫɬɚɬочноɚɫɫоɪɬимɟнɬкомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜкоɬоɪыɟɜключɚɬьɞɜɚкомпонɟнɬɚ ? поɪошкɚконцɟнɬɪɚɬɚɪɚɫɬɜоɪиɬɟльɬɚкжɟнɟɫколькокомпонɟнɬоɜ ? ɪɚɫɬɜоɪиɬɟлɟйПоɫлɟɞнийяɜляɟɬɫянɚиɛолɟɟпɪоɛлɟмнымпɪɟɞпопɪоɫɬоɪɚɫɬɜоɪɟниɟОɫоɛɟннооɫɬɪоɫɬоиɬɜопɪоɫɫоɯɪɚнɟнияɪильноɫɬиɚпиɪоɝɟнноɫɬикомɛиниɪоɜɚнныɯɮɭзионныɯɪɚɫɬɜоɪоɜизɝоɬоɜлɟнныɯзɚɪɭɛɟжныɯиɫɬочникоɜɭɪоɜɟньконɬɚминɚциикомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜпɪиɝоɬоɜлɟнныɯɚɫɟпɬичɟɫкиɯлɚминɚɪномпоɬокɟɫɬɟɪильноɝоɜозɞɭɯɚɚɫɫиɫɬɟнɬɫкойоɬɞɟлɟнииɫоɫɬɚɜляɟɬɫооɬɜɟɬɫɬɜɟнно ? Цɟлью иɫɫлɟɞоɜɚнияяɜилоɫьизɭчɟниɟɚнɚлизɜɚɪиɚнɬоɜэкɫɬɟмпоɪɚльноɝоизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионноɝоɜɜɟɞɟнияɜоɞɫɬɜɟнныɯɚпɬɟкɚɯМɚɬɟɪиɚлымɟɬоɞыМɟɬоɞолоɝичɟɫкойоɫноɜойиɫɫлɟɞоɜɚнияɫɬɚлпоɞɯоɞпозɜоляюключɟɜыɟэлɟмɟнɬыɞɜɭɯɜɚɪиɚнɬоɜэкɫɬɟмпоɪɚльноɝоизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионноɝоɜɜɟɞɟнияɞоɜɚниииɫпользоɜɚнымɟɬоɞылоɝичɟɫкоɝоɮɭнкционɚльноɝоɚнɚлизɚɊɟзɭльɬɚɬыоɛɫɭжɞɟниɟɫооɬɜɟɬɫɬɜииɫɬɜɭющɟйɎɟɞɟɪɚльныйзɚкон 61-ɮɚɪмɚкопɟйныɟɫɬɚɬьи XIII, ПɪикɚзПɪикɚз 309, Пɪикɚз 706ɜɪɚчɟɛнымнɚзнɚчɟниямɚпɬɟкɚɯмɟɞицинɫкиɯɞɜɚɜɚɪиɚнɬɚмɟлкоɫɟɪийноɝоэкɫɬɟмпоɪɚльноɝоизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионɪɚɫɬɜоɪоɜ [9, 10, 11]: ɜɚɪиɚнɬ ? изɝоɬоɜлɟниɟиɫпользоɜɚниɟмклɚɫɫичɟɫкоймноɝоɫɬɚɞийнойɬɟɯнолоɝичɟɫкойɫɯɟɮɚɪмɚцɟɜɬичɟɫкиɯɫɭɛɫɬɚнцийɜɫпомоɝɚɬɟльɜɟщɟɫɬɜɜоɞыɜɚɪиɚнɬ ? изɝоɬоɜлɟниɟиɫпользоɜɚниɟмминимɚльноɝоколичɟɫɬɜɚɫɬɚɞийɬɟɯнолоɝичɟɫкоɝопɪоцɟɫɫɚпɪомышлɟнноɝоɜоɞɫɬɜɚɪɚционɚльноɝоɜɚɪиɚнɬɚнɟоɛɯоɞимопɪоɜɟɫɬиɚнɚлизоцɟнкойоɫноɜɞоɫɬоинɫɬɜнɟɞоɫɬɚɬкоɜɬɚɛлɊиɫɭнокКɪиɬичɟɫкиɟпɚɪɚмɟɬɪыпɪоцɟɫɫɚизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜоɬɞɟлɟнияɯPharmacy & Pharmacology V. 5 N 4, 2017ɌɚɛлицɚɋɪɚɜниɬɟльныйɜозможныɯɜɚɪиɚнɬоɜизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯлɟкɚɪɫɬɜɟнныɯпɪɟпɚɪɚɬоɜинɮɭзионноɝоɜɜɟɞɟнияОцɟниɜɚɟмыйпɚɪɚмɟɬɪПɟɪɜыйɜɚɪиɚнɬȼɬоɪойɜɚɪиɚнɬɎɚɪмɚцɟɜɬичɟɫкɚяэкɫпɟɪɬизɚɫоɜмɟɫɬимоɫɬьПɪоɜоɞиɬɫяоɛязɚɬɟльноɫооɬɜɟɬПɪикɚзɚми 1175 ПɪоɜоɞиɬɫяоɛязɚɬɟльноɫооɬɜɟɬПɪикɚзɚми 1175 ɌɪɟɛоɜɚнияпомɟщɟниямпɟɪɫонɚлɭизɝоɬоɜɚɫɟпɬичɟɫкиɟɫооɬɜɟɬɫɬɜииПɪикɚзɚмиɚɫɟпɬичɟɫкиɟɫооɬɜɟɬɫɬɜииПɪикɚзɚмиИɫɯоɞныɟкомпонɟнɬыɎɚɪмɚцɟɜɬичɟɫкиɟɫɭɛɫɬɚнцииȼɫпомоɝɚɬɟльныɟɜɟщɟɫɬɜɚȼоɞɚɋɬɟɪильныɟлɟкɚɪɫɬɜɟнныɟɪɚɬыɪɚɫɬɜоɪɚконцɟнɬɪɚɬɚɮлɚконɚɯɚмпɭлɚɯɋɬɟɪильныɟлɟкɚɪɫɬɜɟнныɟпɪɟпɚɪɚɬылиоɮилизɚɬɚпоɪошкɚɮлɚконɚɯȼоɞɚɌɪɟɛоɜɚнияизɝоɬоɜлɟниюИɞɟнɬичныɟɫооɬɜɟɬɫɬɜииПɪикɚзомɫооɬɜɟɬɫɬɜииПɪикɚзомɌɟɯнолоɝичɟɫкɚяɫɯɟмɚȼɫɟɫɬɚɞииɬɟɯнолоɝичɟɫкоɝопɪоцɟɫɫɚизɝоɬоɜлɟнияинɮɭзионныɯɪɚɫɬɜоɪоɜɫооɬɜɟɬɫɬɜииПɪикɚзомМинимɚльноɟколичɟɫɬɜоɫɬɚɞийɬɟɯнолоɝичɟɫкоɝопɪоцɟɫɫɚОɛоɪɭɞоɜɚниɟȼɫооɬɜɟɬɫɬɜииɬɪɟɛоɜɚниямимɚɬиɜныɯɞокɭмɟнɬоɜɜɫɟɯɫɬɚɞияɯɬɟɯнолоɝичɟɫкоɝопɪоцɟɫɫɚɍɫɬɚноɜкɚпоɬокомɫɬɟɪильноɝоɜозɞɭɯɚКонɬɪолькɚчɟɫɬɜɚПоɜɫɟмпокɚзɚɬɟлямɫооɬɜɟɬɫɬɜииПɪикɚзомМинимɚльноɟколичɟɫɬɜопокɚзɚɬɟлɟйМɚɪкиɪоɜкɚИɞɟнɬичныɫооɬɜɟɬɫɬɜиипɪикɚзомɫооɬɜɟɬɫɬɜиипɪикɚзомɍɫлоɜияɯɪɚнɟнияИɞɟнɬичныɫооɬɜɟɬɫɬɜииПɪикɚзɚмиɫооɬɜɟɬɫɬɜииПɪикɚзɚмиɪɟзɭльɬɚɬɟпɪоɜɟɞɟнноɝоɚнɚлизɚɞɜɭɯɜɚɪиɚнɬоɜизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜɚпɬɟкɚɯмɟɞицинɫкиɯɭɫɬɚноɜлɟноɫлɟɞɭющɟɟɞɟйɫɬɜɭющиɯнɟзɚɜиɫимоɜɚɪиɚнɬɚполноɫɬьюɫоɜпɚɞɚюɬɬɪɟɛоɜɚнияпɪɟɞɜɚɪиɬɟльнойэкɫпɟɪɬизɟпɪопиɫɟйɫоɜмɟɫɬимоɫɬьпомɟщɟнипɟɪɫонɚлɭизɝоɬоɜлɟниюмɚɪкиɪоɜкɟинɮɭзионɫмɟɫɟйпоɫлɟɞɭющɟɝоПɟɪɟɞизɝоɬоɜлɟниɟмɫмɟɫɟйɫпɟциɚлиɫɬыɫооɬɜɟɬɫɬɜииПɪикɚзɚми 1175 751пɪоɜоɞяɬɮɚɪмɚцɟɜɬичɟɫкɭюэкɫпɟɪɬизɭɝокомпонɟнɬныɯинɮɭзионныɯпɪопиɫɟйпɪɟɞɫоɜмɟɫɬимоɫɬипɪопиɫɚнныɯзɚпɪɟщɚɟɬɫяизɝоɬоɜлɟниɟкомɛиниɪоɜɚнныɯоɬɫɭɬɫɬɜииɮɚɪмɚколоɝичɟɫкойɮɚɪмɚцɟɜɬичɟɫкойɫоɜмɟɫɬимоɫɬиинɮоɪмɚционнымиɫɬочникомɫоɜмɟɫɬимоɫɬикомпонɟнɬоɜинɮɭзионныɯпɪопиɫɟйяɜляɟɬɫяинɫɬɪɭкциямɟɞицинɫкомɭмɟɞицинɫкоɝоɪɚзмɟщɟннɚяɫɚйɬɟɝоɫɭɞɚɪɫɬɜɟнноɝоɪɟɟɫɬɪɚwww.grls.rosminzdrav.ru, ɪɚзɞɟлȼзɚимоɞɟйɫɬɜиɟɞɪɭɝимилɟкɚɪɫɬɜɟннымипɪɟпɚɪɚɬɚмиɫооɬɜɟɬɫɬɜииПɪикɚзɚ 751изɝоɬоɜлɟкɚɪɫɬɜɟнныɯпɪɟпɚɪɚɬоɜоɫɭщɟɫɬɜляɟɬɫяоɬɜɟчɚющиɯɫɚниɬɚɪноэпиɞɟмиолоɝичɟɫкимɬɪɟɛоɜɚниямɋɚниɬɚɪныɟɬɪɟɛоɜɚнияпомɟщɟниямоɛоɪɭɞоɜɚниюɚɫɟпɬичɟɫкоɝоɛлокɚоɛознɚчɟныɪɚзɞɟлɟ 4 Пɪикɚзɚ 309 ɫоɞɟɪжɚɬоɫноɜополɚɝɚющɭюинɮоɪмɚциюɛоɬыɚɫɟпɬичɟɫкоɝоɛлокɚОɫоɛоɝоɜнимɚниязɚɫлɭжиɜɚɟɬкоɬоɪомɪɟкомɟнɞɭɟɬɫяпомощьюɫпɟциɚльноɝооɛоɪɭɞоɜɚнияɫозɞɚниɟɝоɪизонɬɚльныɯɜɟɪɬикɚльныɯпоɬокоɜчиɫɬоɝоɜозɞɭɯɚɜɫɟмпомɟоɬɞɟльныɯлокɚльныɯзонɚɯнɚиɛолɟɟоɬɜɟɬɫɬɜɟнныɯɭчɚɫɬкоɜкɚмɟɪыИзɝоɬоɜлɟниɟмноɝокомпонɟнɬныɯинɮɭзионныɯпɪопиɫɟйоɫɭщɟɫɬɜляɟɬɫяоɫноɜɚнииПɪикɚзɚ 751ɪɚзɞɟл VI. ОɫоɛɟнноɫɬиизɝоɬоɜлɟниялɟкɚɪɫɬɜɟнныɯɮоɪмɚɫɟпɬичɟɫкиɯɬɪɟɛоɜɚнияɛɭɞɭɬɟɞинымиизɝоɬоɜлɟнияпɟɪɜомɭɜɬоɪомɭɜɚɪиɚнɬɭизɝоɬоɜлɟниюɚɫɟпɬичɟпɪɟɞъяɜляюɬɫяɬɪɟɛоɜɚниянɚпɪɚɜɫɜɟɞɟниɟминимɭмɭɪиɫкɚмикɪооɪɝɚнизмɚмимɟɯɚничɟɫкимиɫооɬɜɟɬɫɬɜииɬɚкжɟзɚпɪɟщɚɟɬɫяноɜɪɟмɟнноɟизɝоɬоɜлɟниɟоɞномɪɚɛочɟммɟɫɬɟнɟɫколькиɯинɮɭзионныɯɪɚɫɬɜоɪоɜɫоɞɟɪжɚщиɯлɟкɚɪɫɬɜɟнныɟɫɪɟɞɫɬɜɚнɚимɟноɜɚнилɟкɚɪɫɬɜɟнныɟɫɪɟɞɫɬɜɚоɞноɝонɚимɟноɜɚконцɟнɬɪɚцияɯМɚɪкиɪоɜкɚпɪиɝоɬоɜлɟнныɯкомɛиниɪоɜɚнныɯлɟкɚɪɫɬɜɟнныɯпɪɟпɚɪɚɬоɜинɮɭзионноɝоɜɜɟɞɟɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬɟɯнолоɝияɛиоɬɟɯнолоɝияPharmaceutical Technology and Biotechnologyɞолжнɚɫооɬɜɟɬɫɬɜоɜɚɬьɬɪɟɛоɜɚниямɭɫɬɚноɜпɪиложɟнии 1 Пɪикɚзɚ 751ɜоɞиɬɫяоɮоɪмлɟниɟɫооɬɜɟɬɫɬɜɭющɟйэɬикɟɬкойлɟкɚɪɫɬɜɟнныɟпɪɟпɚɪɚɬыпɚɪɟнɬɟɪɚльноɝоɜɜɟинɮɭзийЭɬикɟɬкɚɛɟломɫиɝнɚльныйцɜɟɬполяэɬикɟɬкɟɞолжныпɪɟɞɭпɪɟɞиɬɟльныɟɋɬɟɪильнонɟɞоɫɬɭпноммɟɫɬɟɬɪɟɛоɜɚнияпомɟщɟниямоɛознɚчɟны XIII ОɎɋлɟкɚɪɫɬɜɟнɫɪɟɞɫɬɜɎɟɞɟɪɚльномзɚконɟ 61-лɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜПɪикɚ 706пɪиложɟнии 15 ?ɌɪɟɛоɜɚнияɪɟжимɚмлɟкɚɪɫɬɜɟнныɯпɪɟпɚɪɚɬоɜɬɚɛлицɟɊɚɫɬɜоɪыинɮɭзийПɪикɚзɚПɟɪɟчиɫлɟннɚяɭɫɬɚнɚɜлиɜɚɟɬɬɪɟɛоɜɚнияɮɚɪмɚцɟɜɬичɟɫкиɯɫɭɛɫɬɚнцийɜɫпомоɝɚɬɟльныɯɜɟщɟɫɬɜɫɬɪɚняɟɬɫяɜɫɟкоɬоɪыɯɫɬоɜɬоɪойɜɚɪиɚнɬизɝоɬоɜлɟнияимɟюɬɫɭщɟɫɬɜɟнныɟɬɪɟɛоɜɚнияɯиɫɯоɞнымкомпонɟнɬɚмɬɟɯнолоɝичɟɫкойɫɯɟмɟизɝоɬоɜлɟнияиɫпользɭɟмомɭоɛоɪɭɞоɜɚниюконɬɪолюкɚчɟɫɬɜɚпɪоɞолжиɬɟльноɫɬикомɛиниɪоɜɚнныɯɮɭзионныɯэкɫɬɟмпоɪɚльноɝоизɝоɬоɜлɟнияɜɚɪиɚнɬɫооɬɜɟɬɫɬɜииɫɬɚɬьɟй 56 ИзɝоɬоɜлɟниɟоɬпɭɫклɟкɚɪɫɬɜɟнныɯпɪɟпɚɪɚɬоɜɎɟɞɟɪɚльноɝозɚконɚ 61-Пɪикɚзɚ 751кɚчɟɫɬɜɟиɫɯоɞныɯкомпонɟнɬоɜизɝоɬоɜлɟнияинɮɭзионныɯɫмɟɫɟйɞолжныиɫпользоɜɚɬьɫяɮɚɪмɚцɟɜɬичɟɫкиɟɫɭɛɫɬɚнцииɜключɟнныɟɫооɬɜɟɬɫɬɜɟнɝоɫɭɞɚɪɫɬɜɟнныйɪɟɟɫɬɪлɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜмɟɞицинɫкоɝоɭɫɬɚноɜлɟнномɪяɞкɟɬɚкжɟɫооɬɜɟɬɫɬɜииɮɚɪмɚкопɟйɫɬɚɬьɟйОɎɋЛɟкɚɪɫɬɜɟнныɟпɚɪɟнɬɟɪɚльноɝоиɫпользоɜɚнияɫоɫɬɚɜɟинɮɭзионныɯɪɚɫɬɜоɪоɜɜɫпомоɝɚɬɟльныɟɜɟщɟɫɬɜɚнɚпɪимɟɪɫɬɚɛилизɚɬоɜоɞɚИнɮɭзионныɟлɟкɚɪɫɬɜɟнɮоɪмыɞолжныизоɬоничнычɟлоɜɟкɚɞолжныɫоɞɟɪжɚɬьконɫɟɪɜɚнɬоɜȼɫɟиɫɯоɞныɟкомпоɞолжнынɚɞлɟжɚщɟɝокɚчɟɫɬɜɚɫооɬɜɟɬɫɬɜоɜɚɬьɬɪɟɛоɜɚниямизɞɚнияПɪинципиɚльнооɬличɚɟɬɫяɬɟɯнолоɝичɟɫкɚяɫɯɟмɚизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯИзɝоɬоɜлɟниɟпɟɪɜомɭɜɚɪиɚнɬɭɜключɚɟɬɜɫɟɫɬɚɞииɬɟɯнолоɝичɟɫкоɝопɪоцɟɫɫɚпоɫɬɚɞийнымконɬɪолɟмпɪиɝоɬоɜлɟнныɯɪɚɫɬɜоɪоɜоɫноɜɚнииɬɪɟɛоɜɚнийПɪикɚзɚПоɞɝоɬоɜиɬɟльнɚяɫɬɚɞияɜключɚɟɬпоɞɝоɬоɜɜоɞыпомɟщɟнияпɟɪɫонɚлɚоɛоɪɭɞоɜɚнияпоɫɭɭкɭпоɪочныɯɫɪɟɞɫɬɜɜɫпомоɝɚɬɟльныɯмɚɬɟɪиɚлоɜɫооɬɜɟɬɫɬɜииПɪикɚзɚми 309 751оɫноɜномɭоɛоɪɭɞоɜɚниюкоɬоɪоɟиɫпользɭɟɬɫяпɟɪɜойɫɬɚɞииɬɟɯнолоɝичɟɫкоɝопɪоцɟɫɫɚоɬноɫяɬɫяɚкɜɚɞиɫɬилляɬоɪыполɭчɟнияɚпиɪоɝɟннойɜоɞыɛɚкɬɟɪициɞныɟмɚшиныпоɫɭɞыɭкɭпоɪочныɯɫɪɟɞɫɬɜɫɭшильныɟшкɚɮызɚɬоɪыɜозɞɭшнойɬɟкɭчимпɚɪомпоɞɞɚɜлɟниɟмИзɝоɬоɜлɟниɟɪɚɫɬɜоɪɚмɚɫɫооɛъɟмнымɬоɞомɜключɚɟɬпɪоɜɟɞɟниɟнɟоɛɯоɞимыɯɪɚɫчɟɬоɜпоɞɝоɬоɜкиɮɚɪмɚцɟɜɬичɟɫкиɯɫɭɛɫɬɚнцийоɬɜɟшиɜɚниɟɜɫпомоɝɚɬɟльныɯɜɟщɟɫɬɜоɬɜɟшиɜɚниɟɪɚɫɬɜоɪиɬɟляоɬмɟɪиɜɚниɟɜоɞыɪɚɫɬɜоɪɟниɟɮɚɪмɚцɟɜɬичɟɫкиɯɫɭɛɫɬɚнцийизоɬониɪɭющиɯɫɬɚɛилизиɪɭющиɯɜɟщɟɫɬɜнɟоɛɯоɞимоɫɬиконɬɪолькɚчɟɫɬɜɚпɪиɝоɬоɜлɟнноɝоɪɚɫɬɜоɪɚɜɬоɪойɫɬɚɞииɬɟɯнолоɝичɟɫкоɝопɪоцɟɫɫɚкɚчɟɫɬɜɟоɛоɪɭɞоɜɚнияиɫпользɭюɬɫяɜɟɫымɟшɚлкиɎильɬɪɚцияɮɚɫоɜкɚɜключɚяɬɜоɪоɜɮлɚконыпоɫлɟɞɭющɟйɭкɭпоɪкоймɚɪкиɪоɜкойпɪоɜɟɞɟниɟмконɬɪолякɚчɟɫɬɜɚɪɚɫɬɜоɪɚИнɮɭзионныɟɪɚɫɬɜоɪыɮильɬɪɭюɬɫяиɫпользоɜɚɮильɬɪоɜɚльныɯмɚɬɟɪиɚлоɜɭɫɬɚноɜокɎильɬɪоɜɚниɟɪɚɫɬɜоɪɚɫочɟɬɚɟɬɫяоɞноɜɪɟмɟннымɪозлиɜомɟɝопоɞɝоɬоɜлɟнныɟɮлɚконыкоɬоɪыɟɭкɭпоɪиɜɚюɬɫяпɪоɛкɚмиИнɬɟɪɜɚлнɚчɚлɚизɝоɬоɜлɟнияинъɟкционноɝоинɮɭзионноɝоɪɚɫɬɜоɪɚɞолжɟнпɪɟɜышɚɬь 3-ОцɟнкɚкɚчɟɫɬɜɚинɮɭзионныɯɪɚɫɬɜоɪоɜпɪоɜоɞиɬɫяоɬɫɭɬɫɬɜиюмɟɯɚничɟɫкиɯɜключɟнийзнɚчɟпоɞлинноɫɬиколичɟɫɬɜɟнномɭɫоɞɟɪжɚлɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜɫоɞɟɪжɚниюизоɬониɪɭɫɬɚɛилизиɪɭющиɯɜɟщɟɫɬɜкɚчɟɫɬɜɟоɛоɪɭɞоɜɚнияɬɪɟɬьɟйɫɬɚɞииɬɟɯнолоɝичɟɫкоɝопɪоцɟɫɫɚиɫпользɭюɬɫяɭɫɬɚноɜкиɮильɬɪɚцииɞозɚɬоɪылɟкɚɪɫɬɜɟнныɯɮоɪмɭɫɬɚноɜкиɪозлиɜɚɪɚɫɬɜоɪоɜɮлɚконыIV. ɋɬɟɪилизɚцияИнɮɭзионныɟɪɚɫɬɜоɪылизɭюɬɫяɫооɬɜɟɬɫɬɜииɬɪɟɛоɜɚниямиɪɟжимɚмɭкɚзɚннымиɬɚɛлицɟ 1 пɪиложɟ 15 Пɪикɚзɚ 751ɞопɭɫкɚɟɬɫяɪɚɫɬɜоɪоɜоɛъɟмомɛолɟɟ 1 лиɬɪɚпоɜɬоɪнɚяинɮɭзионныɯɬɜоɪоɜПɪоцɟɫɫɞолжɟноɛɟɫпɟчиɜɚɬьэɮɮɟкɬиɜноɫɬьɜɫɟɝооɛъɟмɚзɚɝɪɭзкиКонɬɪольпɚɪɚмɟɬɪоɜэɮɮɟкɬиɜноɫɬиɬɟɪмичɟɫкиɯмɟɬоɞоɜоɫɭщɟɫɬɜляɟɬɫяпомощьюконɬɪольноизмɟɪиɬɟльныɯɯимичɟɫкиɯɛиолоɝичɟɫкиɯɬɟɫɬоɜɊɟжимыиɫɯоɞныɯлɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜизɝоɬоɜлɟнныɯинɮɭзионɪɚɫɬɜоɪоɜɬɚкжɟɜɫпомоɝɚɬɟльныɯмɚɬɟɪиɚпоɫɭɞыɪɟɝиɫɬɪиɪɭюɬɫяжɭɪнɚлɟɪɟɝиɫɬɪɚɪɟжимɚиɫɯоɞныɯлɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜизɝоɬоɜлɟнныɯлɟкɚɪɫɬɜɟнныɯпɪɟпɚɪɚɬоɜɜɫпомоɝɚɬɟльныɯмɚɬɟɪиɚлоɜпоɫɭɞыпɪочиɯɬɟɪиɚлоɜчɟɬɜɟɪɬойɫɬɚɞииɬɟɯнолоɝичɟɫкоɝопɪоцɟɫɫɚPharmacy & Pharmacology V. 5 N 4, 2017иɫпользɭюɬɫяɫɬɟɪилизɚɬоɪыɬɟкɭпɚɪомпоɞɞɚɜлɟниɟмɚɜɬоклɚɜыV. КонɬɪолькɚчɟɫɬɜɚКонɬɪолькɚчɟɫɬɜɚɪɚɫɬɜоɪоɜоɫɭщɟɫɬɜляюɬɫяɫооɬɜɟɬɫɬɜииПɪикɚзом 751ɬɪɟɛоɜɚниямиȽоɫɭɞɚɪɫɬɜɟннойɮɚɪмɚкопɟи XIII изɞɚнияиноɝоɞокɭмɟнɬɚконɬɪолякɚчɟɫɬɜɚОцɟнкɚкɚчɟɫɬɜɚинɮɭзионныɯɪɚɫɬɜоɪоɜпоɫлɟпɪоɜоɞиɬɫяоɬɫɭɬɫɬɜиюмɟɯɚничɟɫкиɯɜключɟнийпɪоɜɟɪкɟноминɚльноɝооɛъɟмɚɪозлиɜɟɮлɚконызнɚчɟниюпоɞлинноколичɟɫɬɜɟнномɭɫоɞɟɪжɚниюлɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜоɬклонɟниюноминɚльноɝооɛъɟмɚɫиɪоɜɚнноɫɬиɭкɭпоɪкиɫɬɟɪильноɫɬипиɪоɝɟнноɫоɞɟɪжɚниюɛɚкɬɟɪиɚльныɯэнɞоɬокɫиноɜнɟɫооɬɜɟɬɫɬɜииоɞномɭпɟɪɟчиɫлɟнныɯɬɪɟɛоɜɚнийɪɚɫɬɜоɪыяɜляюɬɫянɟɞоɛɪокɚчɟɫɬɜɟннымиПɪоɞолжиɬɟльноɫɬьпɪиɝоɬоɜлɟнныɯкомɛиниɪоɜɚнныɯлɟкɚɪɫɬɜɟнныɯпɪɟпɚɪɚɬоɜинɮɭзионноɝоɜɜɟɞɟнияɭɫɬɚнɚɜлиɜɚɟɬɫяɫооɬɜɟɬɬɪɟɛоɜɚниямиɭкɚзɚннымиɬɚɛлицɟ 1 пɪиложɟния 15 Пɪикɚзɚ 751ɝоɞноɫɬилɟкɚɪɫɬɜɟнныɯпɪɟпɚɪɚɬоɜɜошɟɞшиɯɬɚɛлицɭɫоɫɬɚɜляюɬинɮɭзийɛолɟɟɫɭɬокɌɚкимоɛɪɚзомɜɚɪиɚнɬэкɫɬɟмпоɪɚльноизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɯɚɪɚкɬɟɪизɭɟɬɫяɫложнойɬɟɯнолоɝичɟɫкойɫɯɟмойɛольшимколичɟɫɬɜомɫɬɚɞийнɟоɛɯоɞимоɫɬьюɫпɟциɚльноɝооɛоɪɭɞоɜɚнияизɝоɬоɜлɟɮильɬɪɚцииɪɚɫɬɜоɪоɜɜыɫокойɬɪɭɞоɟмкоɫɬьюпɪоɞолжиɬɟльноɫɬьюɬɟɯнолоɝичɟɫкоɝонɟɫколькиɯɞɟɬɚльнымконɬɪолɟмкɚчɟɫɬɜɚɬɚкжɟоɬɫɭɬɫɬɜиɟмоɮициɚльɫɬɚɛильноɫɬинɟɫколькиɯɫоɜмɟɫɬнойɬɟɪмичɟɫкойпɚɪомпоɞɞɚɜлɟниɟмɬɟмпɟɪɚɬɭɪɟ 120?ɜозможноɫɬиизɝоɬоɜлɟнияɬɚкиɯинɮɭзионныɯɫмɟɫɟйНɚличиɟцɟлоɝокɪиɬичɟɫкиɯɬочɟкпокɚзыɜɚɟɬонɚльноɫɬьиɫпользоɜɚнияпоɞоɛнойɫɯɟмыизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзиɪɚɫɬɜоɪоɜɚпɬɟкиȼɬоɪойɜɚɪиɚнɬНɟоɛɯоɞимооɬмɟɬиɬьчɬоɜɬоɪойɜɚɪиɚнɬизɝоɬоɜлɟнияпɪоɬиɜоɪɟчиɬɬɪɟɛоɜɚниямзɚпɪɟɬɚизɝоɬоɜлɟнияɚпɬɟкɟзɚɪɟɝиɫɬɪиɪоɜɚнныɯпоɫколькɭпɪɟɞполɚиɫпользоɜɚниɟкɚчɟɫɬɜɟиɫɯоɞныɯкомпонɟнɬоɜизɝоɬоɜлɟнияɮоɪмɜыпɭɫкɚ ? ɪɚɫɬɜоɪыконцɟнɬɪɚɬыɮлɚконɚɯɚмпɭлɚɯлиоɮилизɚɬыɮлɚконɚɯɜоɞɚɜыпɭɫкɚɟмыɟɮɚɪмɚцɟɜɬичɟɫкойпɪомышлɟнноɫɬьюɫлɟɞоɜɚɬɟльнозɚɪɟɝиɫɬɪиɪоɜɚнныɟɝоɫɭɞɚɪɫɬɜɟнномɪɟɟɫɬɪɟнɟɞопоɫɬɚɜкипɪомышлɟнноɝопɪоизɜоɞɫɬɜɚɜозможноиɫпользоɜɚниɟкɚчɟɫɬɜɟиɫɯоɞныɯкомпонɟнɬоɜизɝоɬоɜлɟнныɯɚпɬɟкɟПɪикɚзɭИɫɯоɞныɟкомпонɟнɬыизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜɜɬоɪомɭɜɚɪиɚнɬɭоɬɜɟчɚюɬɬɪɟɛоɜɚниямɞокɭмɟнɬоɜɪɟɝлɚмɟнɬиɪɭющиɯизɝоɬоɜлɟниɟкɚзɚɬɟлямɫɬɟɪильноɫɬиɚпиɪоɝɟнноɫɬиизоɬоничноɫɬиизоɜязкоɫɬиɬɚкжɟимɟюɬɞоɫɬɚɬочныйКɚкɫлɟɞɫɬɜиɟɬɪɟɛɭюɬɫпɟциɚльпоɞɝоɬоɜкиɪɚɫчɟɬоɜɫоɞɟɪжɚнияɮɚɪмɚцɟɜɬичɟɫɭɛɫɬɚнцийɪɚɫɬɜоɪиɬɟлɟйɫɬɚɛилизɚɬоɪоɜɬɚкжɟоɬмɟɪиɜɚнияоɬɜɟшиɜɚнияпɪомышлɟнноɝопɪоизɜоɞɫɬɜɚɜɫɟɝɞɚɞоɫɬɚɬочномɚɫɫоɪɬипɪиɫɭɬɫɬɜɭюɬɚпɬɟкɟопɟɪɚɬиɜноɞоɫɬɚɜлɟныПɪинципиɚльнымоɬличиɟмɜɬоɪоɝоɜɚɪиɚнɬɚизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɬɜоɪоɜяɜляɟɬɫяминимɚльноɟколичɟɫɬɜоɫɬɚɞийɬɟɯнолоɝичɟɫкоɝопɪоцɟɫɫɚПоɞɝоɬоɜиɬɟльнɚяɫɬɚɞияɜключɚɟɬпоɞɝоɬоɜкɭпомɟщɟнияпɟɪɫонɚлɚоɛоɪɭɞоɜɚнияɜɫпомоɝɚɬɟльмɚɬɟɪиɚлоɜИзɝоɬоɜлɟниɟɪɚɫɬɜоɪɚоɫɭщɟɫɬɜляɟɬɫяɫмɟшиɜɚнияоɞноɝонɟɫколькиɯɪɚɫɬɜоɋɬɟɪильноɫɬьиɫɯоɞныɯкомпонɟнɬоɜключɚɟɬнɟоɛɯоɞимоɫɬьиɫпользоɜɚнияпɪоɜɟɞɟнияПоɫколькɭпоɜɬоɪнɚяинɮɭзионныɯɪɚɫɬɜоɪоɜзɚпɪɟщɟнɚПɪикɚзɚМинзɞɪɚɜɚ 26.11.2015 751ɬɟɯнолоɝияизɝоɬоɜлɟнияɞолжныоɛɟɫпɟчиɜɚɬьноɫɬьɝоɬоɜоɝопɪоɞɭкɬɚПɪикɚзɚɪɟкомɟнɞɭɟɬизɝоɬоɜлɟниɟпоɞɜɟɪɝɚющиɯɫяɚɫɟпɬичɟɫкиɯлɚминɚɪномɬокɟɫɬɟɪильноɝоɜозɞɭɯɚизɝоɬоɜлɟнияɬɪɟɛɭɟɬɫяɟмкоɫɬипɪоцɟɫɪɚɫɬɜоɪɟнияпɪоиɫɯоɞяɬзɚɜоɞɫкойɭпɚкоɜкɟɮлɚконɟконɬɟйнɟɪɟКонɬɪолькɚчɟɫɬɜɚИзɝоɬоɜлɟнныɟɜɬоɪомɭɜɚɪиɚнɬɭкомɛиниɪоɜɚнныɟинɮɭзионныɟɬɜоɪыпоɞɜɟɪɝɚюɬɫяконɬɪолюкɚчɟɫɬɜɚɫоɝлɚɫноɬɪɟɛоɜɚниям XIII изɞɚнияПɪикɚзɚминимɚльномɭпɟɪɟчнюпокɚзɚɬɟлɟйоɬɫɭɬɫɬɜиюмɟɯɚничɟɫкиɯɜключɟнийнокɪɚɬнопоɫлɟɫмɟшиɜɚнияпоɞлинноɫɬиколичɟɫɬɜɟнномɭɫоɞɟɪжɚниюлɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜɫɬɟɪильноɫɬипиɪоɝɟнноɫɬиɫоɞɟɪжɚниюɛɚкɬɟɪиɚльныɯэнɞоɬокɫиноɜнɟɫооɬɜɟɬɫɬɜииоɞномɭпɟɪɟчиɫлɟнныɯɬɪɟɛоɜɚнийɪɚɫɬɜоɪыяɜляюɬɫянɟɞоɛɪокɚчɟɫɬɜɟннымиОɛоɪɭɞоɜɚниɟɜɫпомоɝɚɬɟльныɟɌɟɯнолоɝияизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭɪɚɫɬɜоɪоɜɜключɚющɚяоɞноɝонɟɫколькиɯɞоɛɚɜлɟниɟконɬɟйнɟɪɬɜоɪиɬɟлɟмопɪɟɞɟляɟɬминимɚльныйоɛоɪɭɞоɜɚния - кɚмɟɪыɫɬолыпоɬокомɫɬɟɪильноɝоɜозɞɭɯɚпɪоцɟɫɫизɝоɬоɜлɟпɟɪɫонɚлиɫпользɭɟɬɚмпɭлɮлɚконоɜПɪоɞолжиɬɟльноɫɬьизɝоɬоɜлɟинɮɭзионныɯɪɚɫɬɜоɪоɜɜɬоɪомɭɜɚɪиɚнɬɭнɟоɛɯоɞимоɭчиɬыɜɚɬьинɫɬɪɭкциймɟɞицинɫкомɭкоɬоɪыɟɜключɚɬьɬɪɟɛоɜɚнияɬɟмпɟɪɚɬɭɪномɭпɪиɝоɬоɜлɟнныɯɪɚɫɬɜоɪоɜНɚпɪимɟɪȺмокɫиклɚɜпɪиɝоɬоɜлɟнияɪɚɫɬɜоɪɚɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬɟɯнолоɝияɛиоɬɟɯнолоɝияPharmaceutical Technology and Biotechnologyɜнɭɬɪиɜɟнноɝоɜɜɟɞɟнияпɪиɝоɬоɜлɟнныйпользоɜɚниɟм 0,9% ɪɚɫɬɜоɪɚнɚɬɪияможɟɬ 4 чɚɫɚɬɟмпɟɪɚɬɭɪɟ +25? 8 ɬɟмпɟɪɚɬɭɪɟЗɚключɟниɟɌɚкимоɛɪɚзомɜɬоɪойɜɚɪиɚнɬэкɫɬɟмпоɪɚльноɝоизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜпɪомышлɟнноɝоизɜоɞɫɬɜɚоɬличɚɟɬɫяпɪоɫɬоɬойɬɟɯнолоɝичɟɫкойɫɯɟмыоɬɫɭɬɫɬɜиɟмɫложныɯɪɚɫчɟɬоɜпоɞɝоɬоɜоɞопоɞɝоɬоɜкɚоɬмɟɪиɜɚниɟоɬɜɟшиɜɚниɟɜɫпомоɝɚɬɟльныɯɜɟщɟɫɬɜɫɬɚɞийɮильɬɪɚцииɜɚɪиɚнɬомконɬɪолякɚчɟɫɬɜɚоɬɫɭɬɫɬɜиɟмɫложноɝооɛоɪɭɞоɜɚЭɬопозɜоляɟɬопɟɪɚɬиɜноɛольшиɯколичɟɫɬɜɚɯизɝоɬɚɜлиɜɚɬькомɛинɚцииинɮɭзионноɝоɜɜɟɞɟнияɚпɬɟкɚɯIntroduction. medicines for infusion administration both as monother--In case of simultaneous administration of two or more medicines in one infusion, the question of the quality of this combination arises [2, 3]. This is due to the tradi-ready solutions) does not allow to ensure the quality, ef, efNowadays in the hospitals providing assistance in stationary conditions, it is traditional to manufacture combined infusion solutions by the nursing staff in pro-technology, each stage of such a scheme is incorrect be-a combined infusion solution, however, the process of its tions is mixing different dosage forms in a single vial or container. Previously, such actions met the de nition of Article 17 of the Federal Law of 22 June 1998 ?On nition of the the At the same time abroad, especially in many countries of Europe, in the United States, and in Australia, the prob-lem of manufacturing quality combined infusion solutions is solved by delegation of powers for extemporaneous manufacturing directly to the pharmacies of medical or-Pharmacy & Pharmacology V. 5 N 4, 2017ganizations [7]. In the Russian Federation, pharmaceutical specialists working in medical organizations providing as- cant contribution to the management of rational pharmacother-Nowadays stationary patients of medical organiza-two components ? medicine (in the form of powder, ly-components ? medicines and solvents. The last option is but mixing different drugs.department conditions is especially acute. According to ow of sterile air, in the treat-The aim of this work was to study and analyze vari-ants of the extemporal manufacture of combined drugs for infusion introduction in hospital pharmacies.Materials and methods. The methodological basis of the study was a systemic approach, which makes it possible to identify the key elements of two different op-medicines for infusion administration. The research uses medical organizations [9, 10, 11]:To choose a rational option, it is necessary to con-the main advantages and disadvantages (Table 1).Table 1 ? Comparative analysis of possible variants of manufacturing combined medicinesEstimated parameterFirst variantSecond variantrders No.1175 and No.751Requirements to premises and per-Requirements for manufacturingSource componentsWater for injectionsRequirements for manufacturingIdenticalTechnology systemAll stages of the technological process ofEquipmentIn accordance with the requirements of owQuality controlFor all indicatorsMinimum of indicatorsMarkingIdenticalStorage conditionsIdenticalcies of medical organizations, the following was es-1. The requirements for preliminary examination of compatibility letters, premises, personnel, manufactur-in accordance with Orders No. 1175 and No. 751n of and pharmaceutical compatibility. The main information ɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬɟɯнолоɝияɛиоɬɟɯнолоɝияPharmaceutical Technology and Biotechnologyregistry www.grls.rosminzdrav.ru, section ?Interaction organization of the operation of the aseptic unit (Para- ows of clear air in The production of multicomponent infusion regimens is carried out on the basis of Order No. 751n, Section VI ?Characteristics of manufacturing dosage forms under aseptic conditions?. These requirements will be the same rst and second versions. Drug manufacturing un-tamination by microorganisms and mechanical particles.nal products with different names or medicinal products ments established in Appendix No. 1 of Order No. 751n. sions? is carried out. The label has a blue signal color in eld on a white background. On the label organization of their storage are indicated in Pharmaco-poea, Federal Law No. 61-FZ, Art. 58 ?Storage of medic-inal products?, Clauses 1-3, Order No. 706n and Annex products?, Table 1 ?Solutions for injection and infusion? of Order No. 751n. The listed documents set general and substances, excipients, drugs and apply to all organiza- rst and second versions of manufacturing cant differences in the requirements for the In accordance with Article 56 ?Manu-tain antimicrobial preservatives. All source components bined infusion mixtures is fundamentally different. Man- rst variant includes all stag-Preparatory stage includes preparation of water, iary materials. In accordance with Orders No. 309 and No. 751n, aqua distillers for the production of pyrogen-free water, bactericidal lamps, dishwashing machines and clo-sures, drying cabinets, sterilizers for air sterilization and owable steam for pressure.The production of a solution by a mass-volumet- l- lter materials and devices. The ltration of the solution is combined with simultaneous lling prepared sterile bottles, which are sealed with sterile stoppers. The interval from the beginning of the manufacture of the injection and infusion solution to ster-As equipment at the third stage of the technological ltration units, dispensers for liquid dosage forms, lling solutions into bottles are used.IV. gimes indicated in Table No. 1 of Appendix No. 15 of Order No. 751n. Do not sterilize solutions larger than ciency of ciency of thermal methods of sterilization Pharmacy & Pharmacology V. 5 N 4, 2017At the fourth stage of the technological process, ster-V. Quality control eld of quality control. Evaluation cation of the nominal volume xity of closure, sterility, pyrogenicity or bacterial endogenous ed in Table No. 1 of Appendix No. 15 of Order No. 751n. The shelf life of drugs not included into Table 1 is not rst version of the extemporal manufacture plex technological scheme, a large number of stages and ltration, sterilization of solutions, high labor-in-to several hours, detailed quality control. It is also char- cial data on the stability of sev-manufacturing such infusion mixtures. The presence of a hospital pharmacy. ed that the sec-manufacturing the drugs, registered in the Russian Feder-ceutical industry, and therefore registered in the public drug register) as the initial components for manufactur-manufacture of sterile drugs for sterility, apyrogenicity, isotonicity, isobaricity and also have a suf cient shelf life. As a consequence, they do not require special prepa-substances, solvents, stabilizers, as well as their meter- cient range of products in the pharmacy, or can be delivered promptly.The principal difference of the second variant of The preparatory stage includes preparation of the by mixing one or more drugs with a solvent. The sterility of the original components of 26.11.2015, No. 751n), the technology and manufac- nished nal ow of sterile air. For manufacturing no capacity is required. Quality control. The combined infusion solutions and quantitative content of drugs, sterility, pyrogenicity inferior.. The technology ow of sterile air. In the manufacturing process, the staff uses . When manufacturing infusion solutions. For example, Amoxiclav powder for the prepa-complex calculations, a number of preparatory oper- ltration and steriliza- ed version of quality control, equip-ment. This gives a possibility to make various combina-quickly and in large quantities.ɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬɟɯнолоɝияɛиоɬɟɯнолоɝияPharmaceutical Technology and BiotechnologyȻиɛлиоɝɪɚɮичɟɫкийОɬɞɟлɟноɜȺɪɫлɚнɛɟкоɜɚМȿЖЛȿКȺɊɋɌȼȿННЫȿПОЛИПɊȺȽМȺЗИЯПɊȺКɌИКȿȼɊȺЧȺȼɪɚчПɊОȻЛȿМЫȼЗȺИМОȾȿЙɋɌȼИЯЛȿКȺɊɋɌȼКОМȻИНИɊОȼȺННОЙɌȿɊȺПИИНоɜɚяɚпɬɟкɚɋолонининɚМиɯɚйлоɜɚɊоɫɬоɜɚМиɯɚйлоɜлɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜ ? ɫоɫɬояниɟпɪоɛлɟмы // ПɟɪɫпɟкɬиɜыɚпɬɟкɬɟзȺпɬɟчнɚяɫɟɬьɊоɫɫииȼɫɟɪоɫɫконɮȿɝоɪоɜɚНɟɜолинɚИЗȽОɌОȼЛȿНИȿЛȿКȺɊɋɌȼȿННЫɏɎОɊМПɊОȻЛȿМЫɌɊȿȻɍЮЩИȿПɊȺȼОȼОȽОȼɟɫɬникɊоɫзɞɪɚɜнɚɞзоɪɚОɊȽȺНИЗȺЦИЯɊȺȻОɌЫɋОɋɌȺȼȿПɊОɎИЛȺКɌИЧȿɋКОȽОПОЛОЖИɌȿЛЬНЫȿȺɋПȿКɌЫɋЛОЖНОɋɌИȾȿЯɌȿЛЬНОɋɌИЗɚмɟɫɬиɬɟльɝлɚɜноɝоɜɪɚчɚ 2011. Ɏɟɞɟɪɚльныйзɚкон 12.04.2010 лɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜ?http://pravo.gov.ru/?://HYPERLINK ?http://pravo.gov.ru/?pravoHYPERLINK ?http://pravo.gov.ru/?.HYPERLINK ?http://pravo.gov.ru/?govHYPERLINK ?http://pravo.gov.ru/?.HYPERLINK ?http://pravo.gov.ɞɚɬɚЯɝɭɞинɚПɪоцɟнкоМиɫикоɜɚОɋОȻȿННОɋɌИɎɍНКЦИОНИɊОȼȺНИЯȻОЛЬНИЧНЫɏɋɌɊȺНȺɏȿȼɊОПȿЙɋКОȽОЗȺɊɍȻȿЖНЫЙɎОɊМИɊОȼȺНИЯКЛИНИЧȿɋКОЙɎȺɊМȺЦИИЛɟкɚɪɫɬɜɟнноɟоɛɟɫпɟчɟниɟɊоɫɫии 2011. Proctor A.E., Rowe E. Outside the hood. Pharmacy Time. 2014. Vol.1. P. 48-51.ПɪикɚзМинзɞɪɚɜɚ 21 окɬɭɬɜɟɪжɞɟнииинɫɬɪɭкцииɫɚниɬɚɪномɭɚпɬɟчныɯɚпɬɟкизмɟнɟниями 24 ɚпɪɟля 2003 gov.ru/?://HYPERLINK ?http://pravo.gov.ru/?pravoHYPERLINK ?http://pravo.gov.ru/?.HYPERLINK ?http://pravo.gov.ru/?govHYPERLINK ?http://pravo.gov.ru/?.HYPERLINK ?http://pravo.gov.ru/?ru (ɞɚɬɚПɪикɚзМинзɞɪɚɜɫоцɪɚзɜиɬия 23.08.2010 ɪɟɞ 28.12.2010) ?ɭɬɜɟɪжɞɟниилɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜ? URL: httpHYPERLINK ?http://pravo.gov.ru/?://HYPERLINK ?http://pravo.gov.ru/?pravoHYPERLINK ?http://pravo.gov.ru/?.HYPERLINK ?http://pravo.gov.ru/?govHYPERLINK ?http://pravo.gov.ru/?.HYPERLINK ?http://pravo.gov.ru/?ru (ɞɚɬɚПɪикɚзМинзɞɪɚɜɚ 26.11.2015 751ɭɬɜɟɪжɞɟнииизɝоɬоɜлɟнияоɬпɭɫкɚлɟкɚɪɫɬɜɟнныɯпɪɟпɚɪɚɬоɜмɟɞицинɫкоɝоɚпɬɟчнымиинɞиɜиɞɭɚльнымипɪɟɞпɪинимɚɬɟлямиɮɚɪмɚцɟɜɬичɟɫкɭюɞɟяɬɟльноɫɬьpravo.gov.ru/?://HYPERLINK ?http://pravo.gov.ru/?pravoHYPERLINK ?http://pravo.gov.ru/?.HYPERLINK ?http://pravo.gov.ru/?govHYPERLINK ?http://pravo.gov.ru/?.HYPERLINK ?http://pravo.gov.ru/?ru (ɞɚɬɚReferencesSychev D.A., Otdelenov V.A., Danilina K., Anikin G., Arslanbekova S. MEZHLEKARSTVENNYYE VZAI-MODEYSTVIYA I POLIPRAGMAZIYA V PRAKTIKE VRACHA [Inter-drug interactions and polypharmacy VrachrachDoctor]. 2013. N 5. Ɋ. 5?8. (In Russ.)2. Zamoschina Ɍ.Ⱥ. PROBLEMY VZAIMODEYSTVIYA LEKARSTV PRI KOMBINIROVANNOY TERAPII [PROBLEMS OF INTERACTION OF DRUGS IN COMBINATION THERAPY]. THERAPY]. New phar-3-1. P. 63-69. (In Russ.)Soloninina A.V., Mikhailova N.V., Rostova N.B., Mikhailov V.G. Obrashcheniye lekarstvennykh sredstv v LPU ? sostoyaniye, problemy, puti resheniya [Treatment of drugs in the health facility - the state, problems, ways of solving]. Perspektivy razvitiya aptek LPU: tez.dokl. Aptechnaya set? Rossii: XIII Vseross. konf. [Prospects of development of pharmacies of medical institutions]. 2008. P. 57?64. (In Russ.)Egorova S.N., Nevolin E.V. APTECHNOYe IZGOTOVLENIYe LEKARSTVENNYKH FORM: PROBLEMY, TREBUYUSHCHIYe PRAVOVOGO RESHENIYA [Pharmaceutical manufacture of dosage forms: problems Vestnik Roszdravnadzoraestnik RoszdravnadzoraBulletin of Roszdravnadzor]. 2013. No.6. P. 36?38. (In Russ.)Ilyin O.M. ORGANIZATSIYA RABOTY APTEKI V SOSTAVE LECHEBNO-PROFILAKTICHESKOGO UCHREZHDENIYA: POLOZHITEL?NYYe ASPEKTY I SLOZHNOSTI OBESPECHENIYA DEYATEL?NOS-TI [Organization of pharmacy work in the medical-prophylactic establishment: positive aspects and dif culties in Zamestitel? glavnogo vracha glavnogo vrachaDeputy Chief Physician]. 2011. No.12 (67). P. 72-76 (In Russ.) 72-76 (In Russ.)nykh sredstv? [?On the circulation of medicines?] URL: http://pravo.gov.ru (access data: 25.04.2017). (In Russ.)Yagudina R.I., Protsenko M.V., Misikov B.B. OSOBENNOSTI FUNKTSIONIROVANIYA BOL?NICHNYKH APTEK V STRANAKH YEVROPEYSKOGO SOYUZA. ZARUBEZHNYY OPYT FORMIROVANIYA SOVREMENNOY KLINICHESKOY FARMATSII [Features of the functioning of hospital pharmacies in the Pharmacy & Pharmacology V. 5 N 4, 2017 5 N 4, 2017Pharmaceutical provision in Russia]. 2011. N 2. P. 72?81. (In Russ.)Proctor A.E., Rowe E. Outside the hood. Pharmacy Time. 2014.Vol. 1. P. 48?51. 48?51.October. 1997 N 309]. ?Ob utverzhdenii instruktsii po sanitarnomu rezhimu aptechnykh organizatsiy (aptek)?[?On approval of instructions on the sanitary regime of pharmacy organizations (pharmacies)?] (s izmeneniyami ot 24 aprelya 2003 g.) [(as amended on April 24, 2003)] URL: http://pravo.gov.ru (access data: 25.04.2017) (In Russ.).ru (access data: 25.04.2017) (In Russ.)eration of 26.11.2015 751 751lekarstvennykh sredstv? [?On the approval of the rules for manufacturing and dispensing medicinal products for medical use by pharmacy organizations, individual entrepreneurs licensed for pharmaceutical activities?] URL: http://pravo.gov.ru (access data: 25.04.2017). (In Russ.)Prikaz Minzdrava RF ot 26.11.2015 g. 751n [On order of the Ministry of Health and Social Development of 706n]. ?Ob utverzhdenii pravil izgotovleniya i otpuska lekarstvennykh preparatov dlya meditsinskogo primeneniya aptechnymi organizatsiyami, individual?nymi predprinimatelyami, ganizatsiyami, individual?nymi predprinimatelyami, of Medicinal Products?] URL: http://pravo.gov.ru (access data: 25.04.2017) (In Russ.) ict of interest ict of interest. - Doctor of Sciences (Pharmacy), Professor, Head of the Department of Phar-macy of Irkutsk State Medical Academy of Postgraduate Education - a branch of the Russian Medical Academy of Continuing Vocational Education of the Ministry of Health of the Russian Federation. Research interests: system research in the eld of improving drug supply in medical organizations that provide assistance in sta-tionary conditions, improving approaches to the system of continuing education of pharmacists. ORCID: orcid.org/0000-0003-4472-4003. E-mail: kovalskaya_gn@ - assistant cal Academy of Postgraduate Education - a branch of the Russian Medical Academy of Continuing Vocation-Federation. Research interests: the technology of sterile dosage forms for infusion, the extemporal production of sterile medicines, the introduction of the GMP standard. ORCID: orcid.org/0000-0002-8568-1372. E-mail: kat-КонɮликɬинɬɟɪɟɫоɜȺɜɬоɪызɚяɜляюɬоɬɫɭɬɫɬɜииконɮликɬɚинɬɟɪɟɫоɜȺɜɬоɪыКоɜɚльɫкɚяȽɚлинɚНиколɚɟɜнɚɞокɬоɪɮɚɪмɚцɟɜɬичɟɫкиɯнɚɭкпɪоɮɟɫɫоɪзɚɜɟɞɭющийкɚɮɟɞɪойɮɚɪмɚцииИɪкɭɬɫкойɝоɫɭɞɚɪɫɬɜɟнноймɟɞицинɫкойɚкɚɞɟмиипоɫлɟɞипломноɝооɛɪɚзоɜɚния ? ɊоɫɫийɫкойɎȽȻɍɊоɫɫийɫкɚямɟɞицинɫкɚяɚкɚɞɟмияпɪоɮɟɫɫионɚльноɝооɛɪɚзоɜɚнияМиниɫɬɟɪɫɬɜɚзɞɪɚɜооɯɪɚнɟнияɊоɫɫийɫкойɎɟɞɟɪɚцииОɛлɚɫɬьнɚɭчныɯинɬɟɪɟɫоɜɫиɫɬɟмныɟиɫɫлɟɞоɜɚнияоɛлɚɫɬиɫоɜɟɪшɟнɫɬɜоɜɚниялɟкɚɪоɛɟɫпɟчɟниямɟɞицинɫкиɯокɚзыɜɚющиɯпомощьɫɬɚционɚɪныɯɭɫлоɜияɯɜɟɪшɟнɫɬɜоɜɚниɟпоɞɯоɞоɜɫиɫɬɟмɟоɛɪɚзоɜɚнияɮɚɪмɚции. ORCID: orcid.org/0000-0003-4472-4003. E-mail: kovalskaya_gn@МиɯɚлɟɜичȿкɚɬɟɪинɚНиколɚɟɜнɚкɚɮɟɞɪыɮɚɪмɚцииИɪкɭɬɫкойɝоɫɭɞɚɪɫɬɜɟнмɟɞицинɫкойɚкɚɞɟмиипоɫлɟɞипломноɝооɛɪɚзоɜɚния ? ɮилиɚлɚɊоɫɫийɫкойɎȽȻɍɊоɫɫийɫкɚямɟɞицинɫкɚяɚкɚɞɟмияпɪоɮɟɫɫионɚльоɛɪɚзоɜɚнияМиниɫɬɟɪɫɬɜɚзɞɪɚɜооɯɪɚнɟнияɊоɫɫийɫкойɎɟɞɟɪɚцииОɛлɚɫɬьнɚɭчныɯинɬɟɪɟɫоɜɬɟɯнолоɝиялɟкɚɪɫɬɜɟнныɯɮоɪмɮɭзионноɝоɜɜɟɞɟнияэкɫɬɟмпоɪɚльноɟизɝоɬоɜлɟниɟлɟкɚɪɫɬɜɟнныɯɜнɟɞɪɟниɟɫɬɚнɞɚɪɬɚ GMP. ORCID: orcid.org/0000-0002-8568-ПоɫɬɭпилɚɪɟɞɚкциюОɬпɪɚɜлɟнɚɞоɪɚɛоɬкɭПɪиняɬɚпɟчɚɬиɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬɟɯнолоɝияɛиоɬɟɯнолоɝияPharmaceutical Technology and BiotechnologyɍȾКˑКˁ˃ʫʺʿОˀʤЛːʻОʫʰʯʧО˃ОʦЛʫʻʰʫКОʺʥʰʻʰˀОʦʤʻʻˏˈʿˀʫʿʤˀʤ˃Оʦʰʻˇ˄ʯʰОʻʻОʧОʿˀОʰʯʦОʪˁ˃ʦʫʻʻˏˈОˀʧʤʻʰʯʤˉʰʱˀОˁˁʰʰКоɜɚльɫкɚяМиɯɚлɟɜичИɪкɭɬɫкɚяɝоɫɭɞɚɪɫɬɜɟннɚямɟɞицинɫкɚяɚкɚɞɟмияпоɫлɟɞипломноɝооɛɪɚзоɜɚнияɊоɫɫийɫкойɎȽȻɍɊоɫɫийɫкɚямɟɞицинɫкɚяɚкɚɞɟмияпɪоɮɟɫɫионɚльноɝооɛɪɚзоɜɚнияɫɬɜɚзɞɪɚɜооɯɪɚнɟнияɊоɫɫийɫкойɎɟɞɟɪɚцииɊоɫɫияЮɛилɟйныйОкɚзɚниɟɮɚɪмɚцɟɜɬичɟɫкойпомощиоɪиɟнɬиɪоɜɚннойпɚциɟнɬɚоɫɭщɟɫɬɜляɟɬɫячɟɪɟзɮɚɪмɚцɟɜɬичɟɫкиɟɫопɪоɜожɞɚɟɬɫяɬɚкиминɟоɛɯоɞимымиɮɭнкциямикɚкконɫɭльɬиɪоɜɚниɟпɪɟɞоɫɬɚɜлɟниɟинɮоɪмɚциилɟкɚɪɫɬɜɟннымпɪɟпɚɪɚɬɚмлɟкɚɪɫɬɜɟннойɬɚкжɟɜключɚɟɬоɛɟɫпɟчɟниɟкɚчɟɫɬɜɟннымиэɮɮɟкɬиɜнымиɛɟзопɚɫнымиэɬомɪольɫɜоɞиɬɫяоɛɟɫпɟчɟниюнɚɫɟлɟнияпɪомышлɟнноɝопɪоизɜоɞɫɬɜɚОɫоɛɟнноɜопɪоɫɜɟɪшɟнɫɬɜоɜɚнияɬɟɯнолоɝииинɮɭзионныɯɪɚɫɬɜоɪоɜнɚзнɚчɚɟмыɯɫɬɚционɚɪныɯɭɫлоɜияɯɬомчиɫлɟкомɛиниɪоɜɚнныɯинɞиɜиɞɭɚльноɝоизɝоɬоɜлɟнияЦɟльюиɫɫлɟɞоɜɚнияяɜилоɫьизɭчɟниɟɜɚɪиэкɫɬɟмпоɪɚльноɝоизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионноɝоɜɜɟɞɟнияпɪоизɜоɞɫɬɜɟнныɯɚпɬɟкɚɯмɟɞицинɫкиɯМɚɬɟɪиɚлымɟɬоɞыМɟɬоɞолоɝичɟɫкойоɫноɜойиɫɫлɟɞоɜɚнияɫɬɚлɫиɫɬɟмныйпоɞɯоɞпозɜоляющийɜыɞɟлиɬьключɟɜыɟэлɟмɟнɬыɞɜɭɯɪɚзличныɯɜɚɪиɚнɬоɜэкɫɬɟмпоɪɚльизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионноɝоɜɜɟɞɟнияиɫɫлɟɞоɜɚниииɫпользоɜɚнымɟɬоɞылоɝичɟɫкоɝоɮɭнкционɚльноɝоɊɟзɭльɬɚɬыоɛɫɭжɞɟниɟнɚɭчныɯиɫɬочникоɜɜопɪоɫɚмизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜнɭжɞɫɬɚционɚɪныɯпокɚзɚлизɝоɬоɜлɟниɟоɫɭщɟɫɬɜляɟɬɫяɊоɫɫийɫкойɎɟɞɟɪɚцииɫɯɟмɟ ? ɭɫлоɜияɯпɪоцɟɞɭɪноɝокɚɛинɟɬɚоɬɞɟлɟнияɚпɬɟкɚɯмɟɞицинɫкиɯɞɜɚɜɚɪиɚнɬɚмɟлкоɫɟɪийноɝоэкɫɬɟмпоɪɚльноɝоизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜиɫпользоɜɚниɟмɮɚɪмɚцɟɜɬичɟɫкиɯɫɭɛɫɬɚнцийиɫпользоɜɚниɟмпɪомышлɟнноɝопɪоизɜоɞɫɬɜɚцɟлоɝоɪяɞɚкɪиɬичɟɫкиɯɬочɟкпɟɪɜоɝоɜɚɪиɚнɬɚпокɚзыɜɚɟɬиɫпользоɜɚнияпоɞоɛнойɫɯɟмыизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜɭɫлоɜияɯмɟɞицинɫкойȼɬоɪойɜɚɪиɚнɬэкɫɬɟмпоɪɚльноɝоизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜоɬличɚɟɬɬɟɯнолоɝичɟɫкойɫɯɟмыоɬɫɭɬɫɬɜиɟмɫложныɯɪɚɫчɟɬоɜɪяɞɚпоɞɝоɬоɜиɬɟльныɯɫɬɚɞийɮильɬɪɚцииɭпɪощɟннымɜɚɪиɚнɬомконɬɪолякɚчɟɫɬɜɚоɬɫɭɬɫɬɜиɟмɫложноɝооɛоɪɭɞоɜɚнияЗɚключɟниɟИзɝоɬоɜлɟниɟкомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜпɪомышлɟнноɝопɪоизɜоɞɫɬɜɚпозɜоляɟɬɛольшиɯколичɟɫɬɜɚɯизɝоɬɚɜлиɜɚɬьɪɚзличныɟкомɛинɚцииинɮɭзионноɝоɜɜɟɞɟнияпɪоɬиɜоɪɟчиɬɞɟйɫɬɜɭющɟмɭзɚконоɞɚɬɟльɫɬɜɭɞɚɟɬɜозможноɫɬьɫмɚɬɪиɜɚɬькɚчɟɫɬɜɟɜɚɪиɚнɬɚизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜɚпɬɟкɚɯмɟɞицинɫкиɯКлючɟɜыɟɫлоɜɚкомɛиниɪоɜɚнныɟлɟкɚɪɫɬɜɟнныɟинɮɭзионноɝоɜɜɟɞɟнияэкɫɬɟмпоизɝоɬоɜлɟниɟмɟɞицинɫкиɟциɬиɪоɜɚнияКоɜɚльɫкɚяМиɯɚлɟɜичЭКɋɌȿМПОɊȺЛЬНОȿИЗȽОɌОȼЛȿНИȿКОМȻИНИɊОȼȺННЫɏЛȿКȺɊɋɌȼȿННЫɏПɊȿПȺɊȺɌОȼИНɎɍЗИОННОȽОПɊОИЗȼОȾɋɌȼȿНОɊȽȺНИЗȺЦИЙɊОɋɋИИɎɚɪмɚцияɮɚɪмɚколоɝияКоɜɚльɫкɚяМиɯɚлɟɜичFor citation:EXTEMPORANEOUS MANUFACTURING OF INTRAVENOUS ADMIXTURES IN HOSPITAL PHARMACIES OF RUSSIAN FEDERATION. Pharmacy & Pharmacology. 2017;5(4):306-317. (In Russ.) Pharmacy & Pharmacology V. 5 N 4, 2017ȼɜɟɞɟниɟМɟɞицинɫкɚяпомощьокɚзыɜɚɟмɚяпɚциɟнɬɚмɫɬɚционɚɪныɯɯɚɪɚкɬɟɪизɭɟɬиɫпользоɜɚниɟмлɟкɚɪɫɬɜɟнныɯɬоɜинɮɭзионноɝоɜɜɟɞɟниякɚккɚчɟɫɬɜɟмоноɬɟɪɚпииɬɚкɮоɪмɚɬɟкомɛиниɪоɜɚнноймɚкоɬɟɪɚпии [1]. оɞноɜɪɟмɟнноɝонɚзнɚчɟɞɜɭɯɛолɟɟоɞнойинɮɭзииɜозникɚɟɬпɪоɫкɚчɟɫɬɜɚкомɛинɚции [2, 3]. Эɬоɫɜязɚноɬɪɚɞиционнымизɝоɬоɜлɟниɟмкомɛиниɪоɜɚнныɯпɪопиɫɟймɟɞицинɫкимиɫɟɫɬɪɚминɟпоɫɪɟɞɫɬɜɟннооɬɞɟлɟниячɬооɬɫɭɬɚнɚлизɚнɚзнɚчɟнияɫоɜмɟɫɬимоɫɬькомпонɟнɬоɜоɬɫɭɬɫɬɜиɟконɬɪолякɚчɟɫɬɜɚɞолжныɯɝоɬоɜыɯɬɜоɪоɜпозɜоляɟɬоɛɟɫпɟчиɬькɚчɟɫɬɜоэɮɮɟкɬиɜноɫɬьɛɟзопɚɫноɫɬьɮɚɪмɚкоɬɟɪɚпии [2, 3]. Нɚ ɫɟɝоɞняшниймɟɞицинɫкиɯокɚзыɜɚющиɯпомощьɫɬɚционɚɪныɯɬɪɚɞиционнымɫчиɬɚɟɬɫяизɝоɬоɜлɟниɟкомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜɫɪɟɞниммɟɞицинɫкимпɟɪɫонɚломпɪоцɟɞɭɪноɝокɚɛинɟɬɚɬочкиɮɚɪмɚцɟɜɬичɟɫкойɬɟɯнокɚжɞыйэɬɚппоɞоɛнойɫɯɟмыяɜляɟɬɫянɟкоɪɪɟкɬнымнɚличияцɟлоɝокɪиɬичɟɫкиɯɪɚмɟɬɪоɜпɪоɛлɟмойэɬоɝоэɬɚпɚяɜляɟɬɫяоɬɫɭɬноɪмɚɬиɜныɯɞокɭмɟнɬоɜɪɟɝлɚмɟнɬиɪɭющиɯизɝоɬоɜлɟниɟкомɛиниɪоɜɚнныɯинɮɭзионныɯɬɜоɪоɜОɬɟчɟɫɬɜɟнныɟɪɭкоɜоɞɫɬɜɚɫɟɫɬɪинɫкиммɚнипɭляциямɜключɚюɬнɟпоɫɪɟɞɫɬɜɟнноɬɟɯникɭɜɜɟɞɟниякомɛиниɪоɜɚнноɝоинɮɭзионноɝоɪɚɫɬɜоɪɚоɞнɚкопɪоцɟɫɫɟɝоизɝоɬоɜлɟнияпɪопиɫыɜɚɟɬɫяɫɭɬиизɝоɬоɜлɟниɟкомɛиниɪоɜɚнныɯинɮɭɪɚɫɬɜоɪоɜ ? эɬоɫмɟшиɜɚниɟкɚɪɫɬɜɟнныɯɮоɪмоɞномɮлɚконɟконɬɟйнɟɪɟпоɞоɛныɟпопɚɞɚлипоɞопɪɟɞɟлɟниɟɎɟɞɟɪɚльноɝозɚконɚ 22 1998 кɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜɚɯкоɬоɪоɟɝлɚɫилоИзɝоɬоɜɚпɬɟчномɜключɚɟɬɜɫɟпɪиɝоɬоɜлɟнияпɟɪɟлиɜɚниялɟкɚɪɫɬɜɟнɮоɪмɪɚзлиɜɚниɟɟмкоɫɬямоɬноɫиɬɫяɮɚɪмɚцɟɜɬичɟɫкойɞɟяɬɟльноɫɬиȾɟйɫɬɜɭющийнɚɫɬоящɟɟɎɟɞɟɪɚльныйзɚкон 12.04.2010 лɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜɞɪɭɝиɟноɪмɚɬиɜнопɪɚɜоɜыɟɚкɬыɫожɚлɟниюɎɟɞɟɪɚльныйзɚкон 61-ɞɚюɬчɟɬкоɝоEXTEMPORANEOUS MANUFACTURING OF INTRAVENOUS ADMIXTURES IN HOSPITAL PHARMACIES OF RUSSIAN FEDERATIONIrkutsk State Medical Academy of Postgraduate Education ? a branch of the Russian Medical Academy of Continuing Vocational Education, 100, Yubileiny, Irkutsk city, Russia, 664079The provision of patient-centered pharmaceutical care is carried out through pharmaceutical organizations and is accompanied by such necessary functions as counseling, provision of information on drugs, monitoring of drug therapy. It also includes ensuring quality, effective and safe drugs. In this case, the role of pharmacies is reduced to providing the population with ready-made products of industrial production. The problem of improving the technol-ogy of infusion solutions assigned in stationary conditions, including combined drugs of individual manufacture is of this work was to study and analyze the options for the extemporaneous manufacture of combined drugs for infusion introduction in hospital pharmacies. The methodological basis of the study was a systemic approach, which makes it possible to identify the key elements of two different options for the extemporaneous manufacture of combined drugs for infusion administration. The research uses methods of logical c sources on the issues of manufacturing of combined infusion solutions for the needs of stationary patients showed that manufacturing is carried out according to the traditional scheme for the Russian Federation, i.e. in the conditions of the procedural room of the department. In pharmacies of medical organizations, two variants of small-scale extemporal manufacture of combined infusion solutions are permissible - using pharmaceutical substances and using sterile drugs of industrial production. The presence of a number of critical points of the rst variant shows the irrationality and limitations of the use of such a scheme for the manufacture of combined infusion solutions in the pharmacy of a medical organization. The second version of the extemporal manufacture of combined infusion solutions is characterized by the simplicity of the techno-logical scheme, the absence of complex calculations, a number of preparatory operations, ltration and sterilization ed version of quality control, and the lack of complex equipment. This allows the rapid and large-scale production of various combinations of drugs for infusion. Manufacturing intravenous admixtures from commercial medicines allows the rapid and large pro-duction of various combinations of drugs for infusion introduction, does not contradict the current legislation, which makes it possible to consider it as the main variant of manufacturing of combined infusion solutions in hospital phar-: combined medications for infusion, extemporaneous manufacturing, medical organizationsɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬɟɯнолоɝияɛиоɬɟɯнолоɝияPharmaceutical Technology and BiotechnologyопɪɟɞɟлɟнияизɝоɬоɜлɟниɟɌɟмɬɟɪминизɝоɬоɜлɟниɟоɬноɫиɬɫямɚцɟɜɬичɟɫкойɞɟяɬɟльноɫɬиɭпоминɚɟɬɫяɬолькоɬɟɯɪɚзɞɟлɚɯкоɬоɪыɟнɟпоɫɪɟɞɫɬɜɟнноɝлɚмɟнɬиɪɭюɬechnology and Biotechnologyȼ ɬо жɟ ɜɪɟмя, зɚ ɪɭɛɟжомчɚɫɬноɫɬиɫɬɪɚнɚɯȺɜɫɬɪɚлиипɪоɛлɟмɚизɝоɬоɜлɟниякɚчɟɫɬɜɟнныɯкомɛиниɪоɜɚнныɯинɮɭɪɚɫɬɜоɪоɜɪɟшɚɟɬɫяпɟɪɟɞɚчиполномочийэкɫɬɟмпоɪɚльномɭизɝоɬоɜлɟниюɫɪɟɞɫɬɜɟнноɚпɬɟкимɟɞицинɫкиɯ [7]. ɮɚɪмɚцɟɜɬичɟɫкиɟɫпɟциɚлиɫɬыɪɚɛоɬɚющиɟмɟɞицинɫкиɯокɚзыɜɚющиɟпомощьпɚциɟнɬɚмɫɬɚционɚɪныɯɬɚкжɟɜнɟɫɬизнɚчиɬɟльныйɜɟɞɟниɟнɚльнойɮɚɪмɚкоɬɟɪɚпииɫоɜмɟɫɬномɟɞицинɫкимиɫпɟциɚлиɫɬɚмиɫɟɝоɞняшнийɫɬɚционɚɪнымɬɚммɟɞицинɫкиɯнɚзнɚчɚɟɬɫяɫɬɚɬочноɚɫɫоɪɬимɟнɬкомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜкоɬоɪыɟɜключɚɬьɞɜɚкомпонɟнɬɚ ? поɪошкɚконцɟнɬɪɚɬɚɪɚɫɬɜоɪиɬɟльɬɚкжɟнɟɫколькокомпонɟнɬоɜ ? ɪɚɫɬɜоɪиɬɟлɟйПоɫлɟɞнийяɜляɟɬɫянɚиɛолɟɟпɪоɛлɟмнымпɪɟɞпопɪоɫɬоɪɚɫɬɜоɪɟниɟОɫоɛɟннооɫɬɪоɫɬоиɬɜопɪоɫɫоɯɪɚнɟнияɪильноɫɬиɚпиɪоɝɟнноɫɬикомɛиниɪоɜɚнныɯɮɭзионныɯɪɚɫɬɜоɪоɜизɝоɬоɜлɟнныɯзɚɪɭɛɟжныɯиɫɬочникоɜɭɪоɜɟньконɬɚминɚциикомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜпɪиɝоɬоɜлɟнныɯɚɫɟпɬичɟɫкиɯлɚминɚɪномпоɬокɟɫɬɟɪильноɝоɜозɞɭɯɚɚɫɫиɫɬɟнɬɫкойоɬɞɟлɟнииɫоɫɬɚɜляɟɬɫооɬɜɟɬɫɬɜɟнно ? Цɟлью иɫɫлɟɞоɜɚнияяɜилоɫьизɭчɟниɟɚнɚлизɜɚɪиɚнɬоɜэкɫɬɟмпоɪɚльноɝоизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионноɝоɜɜɟɞɟнияɜоɞɫɬɜɟнныɯɚпɬɟкɚɯМɚɬɟɪиɚлымɟɬоɞыМɟɬоɞолоɝичɟɫкойоɫноɜойиɫɫлɟɞоɜɚнияɫɬɚлпоɞɯоɞпозɜоляюключɟɜыɟэлɟмɟнɬыɞɜɭɯɜɚɪиɚнɬоɜэкɫɬɟмпоɪɚльноɝоизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионноɝоɜɜɟɞɟнияɞоɜɚниииɫпользоɜɚнымɟɬоɞылоɝичɟɫкоɝоɮɭнкционɚльноɝоɚнɚлизɚɊɟзɭльɬɚɬыоɛɫɭжɞɟниɟɫооɬɜɟɬɫɬɜииɫɬɜɭющɟйɎɟɞɟɪɚльныйзɚкон 61-ɮɚɪмɚкопɟйныɟɫɬɚɬьи XIII, ПɪикɚзПɪикɚз 309, Пɪикɚз 706ɜɪɚчɟɛнымнɚзнɚчɟниямɚпɬɟкɚɯмɟɞицинɫкиɯɞɜɚɜɚɪиɚнɬɚмɟлкоɫɟɪийноɝоэкɫɬɟмпоɪɚльноɝоизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионɪɚɫɬɜоɪоɜ [9, 10, 11]: ɜɚɪиɚнɬ ? изɝоɬоɜлɟниɟиɫпользоɜɚниɟмклɚɫɫичɟɫкоймноɝоɫɬɚɞийнойɬɟɯнолоɝичɟɫкойɫɯɟɮɚɪмɚцɟɜɬичɟɫкиɯɫɭɛɫɬɚнцийɜɫпомоɝɚɬɟльɜɟщɟɫɬɜɜоɞыɜɚɪиɚнɬ ? изɝоɬоɜлɟниɟиɫпользоɜɚниɟмминимɚльноɝоколичɟɫɬɜɚɫɬɚɞийɬɟɯнолоɝичɟɫкоɝопɪоцɟɫɫɚпɪомышлɟнноɝоɜоɞɫɬɜɚɪɚционɚльноɝоɜɚɪиɚнɬɚнɟоɛɯоɞимопɪоɜɟɫɬиɚнɚлизоцɟнкойоɫноɜɞоɫɬоинɫɬɜнɟɞоɫɬɚɬкоɜɬɚɛлɊиɫɭнокКɪиɬичɟɫкиɟпɚɪɚмɟɬɪыпɪоцɟɫɫɚизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜоɬɞɟлɟнияɯPharmacy & Pharmacology V. 5 N 4, 2017ɌɚɛлицɚɋɪɚɜниɬɟльныйɜозможныɯɜɚɪиɚнɬоɜизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯлɟкɚɪɫɬɜɟнныɯпɪɟпɚɪɚɬоɜинɮɭзионноɝоɜɜɟɞɟнияОцɟниɜɚɟмыйпɚɪɚмɟɬɪПɟɪɜыйɜɚɪиɚнɬȼɬоɪойɜɚɪиɚнɬɎɚɪмɚцɟɜɬичɟɫкɚяэкɫпɟɪɬизɚɫоɜмɟɫɬимоɫɬьПɪоɜоɞиɬɫяоɛязɚɬɟльноɫооɬɜɟɬПɪикɚзɚми 1175 ПɪоɜоɞиɬɫяоɛязɚɬɟльноɫооɬɜɟɬПɪикɚзɚми 1175 ɌɪɟɛоɜɚнияпомɟщɟниямпɟɪɫонɚлɭизɝоɬоɜɚɫɟпɬичɟɫкиɟɫооɬɜɟɬɫɬɜииПɪикɚзɚмиɚɫɟпɬичɟɫкиɟɫооɬɜɟɬɫɬɜииПɪикɚзɚмиИɫɯоɞныɟкомпонɟнɬыɎɚɪмɚцɟɜɬичɟɫкиɟɫɭɛɫɬɚнцииȼɫпомоɝɚɬɟльныɟɜɟщɟɫɬɜɚȼоɞɚɋɬɟɪильныɟлɟкɚɪɫɬɜɟнныɟɪɚɬыɪɚɫɬɜоɪɚконцɟнɬɪɚɬɚɮлɚконɚɯɚмпɭлɚɯɋɬɟɪильныɟлɟкɚɪɫɬɜɟнныɟпɪɟпɚɪɚɬылиоɮилизɚɬɚпоɪошкɚɮлɚконɚɯȼоɞɚɌɪɟɛоɜɚнияизɝоɬоɜлɟниюИɞɟнɬичныɟɫооɬɜɟɬɫɬɜииПɪикɚзомɫооɬɜɟɬɫɬɜииПɪикɚзомɌɟɯнолоɝичɟɫкɚяɫɯɟмɚȼɫɟɫɬɚɞииɬɟɯнолоɝичɟɫкоɝопɪоцɟɫɫɚизɝоɬоɜлɟнияинɮɭзионныɯɪɚɫɬɜоɪоɜɫооɬɜɟɬɫɬɜииПɪикɚзомМинимɚльноɟколичɟɫɬɜоɫɬɚɞийɬɟɯнолоɝичɟɫкоɝопɪоцɟɫɫɚОɛоɪɭɞоɜɚниɟȼɫооɬɜɟɬɫɬɜииɬɪɟɛоɜɚниямимɚɬиɜныɯɞокɭмɟнɬоɜɜɫɟɯɫɬɚɞияɯɬɟɯнолоɝичɟɫкоɝопɪоцɟɫɫɚɍɫɬɚноɜкɚпоɬокомɫɬɟɪильноɝоɜозɞɭɯɚКонɬɪолькɚчɟɫɬɜɚПоɜɫɟмпокɚзɚɬɟлямɫооɬɜɟɬɫɬɜииПɪикɚзомМинимɚльноɟколичɟɫɬɜопокɚзɚɬɟлɟйМɚɪкиɪоɜкɚИɞɟнɬичныɫооɬɜɟɬɫɬɜиипɪикɚзомɫооɬɜɟɬɫɬɜиипɪикɚзомɍɫлоɜияɯɪɚнɟнияИɞɟнɬичныɫооɬɜɟɬɫɬɜииПɪикɚзɚмиɫооɬɜɟɬɫɬɜииПɪикɚзɚмиɪɟзɭльɬɚɬɟпɪоɜɟɞɟнноɝоɚнɚлизɚɞɜɭɯɜɚɪиɚнɬоɜизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜɚпɬɟкɚɯмɟɞицинɫкиɯɭɫɬɚноɜлɟноɫлɟɞɭющɟɟɞɟйɫɬɜɭющиɯнɟзɚɜиɫимоɜɚɪиɚнɬɚполноɫɬьюɫоɜпɚɞɚюɬɬɪɟɛоɜɚнияпɪɟɞɜɚɪиɬɟльнойэкɫпɟɪɬизɟпɪопиɫɟйɫоɜмɟɫɬимоɫɬьпомɟщɟнипɟɪɫонɚлɭизɝоɬоɜлɟниюмɚɪкиɪоɜкɟинɮɭзионɫмɟɫɟйпоɫлɟɞɭющɟɝоПɟɪɟɞизɝоɬоɜлɟниɟмɫмɟɫɟйɫпɟциɚлиɫɬыɫооɬɜɟɬɫɬɜииПɪикɚзɚми 1175 751пɪоɜоɞяɬɮɚɪмɚцɟɜɬичɟɫкɭюэкɫпɟɪɬизɭɝокомпонɟнɬныɯинɮɭзионныɯпɪопиɫɟйпɪɟɞɫоɜмɟɫɬимоɫɬипɪопиɫɚнныɯзɚпɪɟщɚɟɬɫяизɝоɬоɜлɟниɟкомɛиниɪоɜɚнныɯоɬɫɭɬɫɬɜииɮɚɪмɚколоɝичɟɫкойɮɚɪмɚцɟɜɬичɟɫкойɫоɜмɟɫɬимоɫɬиинɮоɪмɚционнымиɫɬочникомɫоɜмɟɫɬимоɫɬикомпонɟнɬоɜинɮɭзионныɯпɪопиɫɟйяɜляɟɬɫяинɫɬɪɭкциямɟɞицинɫкомɭмɟɞицинɫкоɝоɪɚзмɟщɟннɚяɫɚйɬɟɝоɫɭɞɚɪɫɬɜɟнноɝоɪɟɟɫɬɪɚwww.grls.rosminzdrav.ru, ɪɚзɞɟлȼзɚимоɞɟйɫɬɜиɟɞɪɭɝимилɟкɚɪɫɬɜɟннымипɪɟпɚɪɚɬɚмиɫооɬɜɟɬɫɬɜииПɪикɚзɚ 751изɝоɬоɜлɟкɚɪɫɬɜɟнныɯпɪɟпɚɪɚɬоɜоɫɭщɟɫɬɜляɟɬɫяоɬɜɟчɚющиɯɫɚниɬɚɪноэпиɞɟмиолоɝичɟɫкимɬɪɟɛоɜɚниямɋɚниɬɚɪныɟɬɪɟɛоɜɚнияпомɟщɟниямоɛоɪɭɞоɜɚниюɚɫɟпɬичɟɫкоɝоɛлокɚоɛознɚчɟныɪɚзɞɟлɟ 4 Пɪикɚзɚ 309 ɫоɞɟɪжɚɬоɫноɜополɚɝɚющɭюинɮоɪмɚциюɛоɬыɚɫɟпɬичɟɫкоɝоɛлокɚОɫоɛоɝоɜнимɚниязɚɫлɭжиɜɚɟɬкоɬоɪомɪɟкомɟнɞɭɟɬɫяпомощьюɫпɟциɚльноɝооɛоɪɭɞоɜɚнияɫозɞɚниɟɝоɪизонɬɚльныɯɜɟɪɬикɚльныɯпоɬокоɜчиɫɬоɝоɜозɞɭɯɚɜɫɟмпомɟоɬɞɟльныɯлокɚльныɯзонɚɯнɚиɛолɟɟоɬɜɟɬɫɬɜɟнныɯɭчɚɫɬкоɜкɚмɟɪыИзɝоɬоɜлɟниɟмноɝокомпонɟнɬныɯинɮɭзионныɯпɪопиɫɟйоɫɭщɟɫɬɜляɟɬɫяоɫноɜɚнииПɪикɚзɚ 751ɪɚзɞɟл VI. ОɫоɛɟнноɫɬиизɝоɬоɜлɟниялɟкɚɪɫɬɜɟнныɯɮоɪмɚɫɟпɬичɟɫкиɯɬɪɟɛоɜɚнияɛɭɞɭɬɟɞинымиизɝоɬоɜлɟнияпɟɪɜомɭɜɬоɪомɭɜɚɪиɚнɬɭизɝоɬоɜлɟниюɚɫɟпɬичɟпɪɟɞъяɜляюɬɫяɬɪɟɛоɜɚниянɚпɪɚɜɫɜɟɞɟниɟминимɭмɭɪиɫкɚмикɪооɪɝɚнизмɚмимɟɯɚничɟɫкимиɫооɬɜɟɬɫɬɜииɬɚкжɟзɚпɪɟщɚɟɬɫяноɜɪɟмɟнноɟизɝоɬоɜлɟниɟоɞномɪɚɛочɟммɟɫɬɟнɟɫколькиɯинɮɭзионныɯɪɚɫɬɜоɪоɜɫоɞɟɪжɚщиɯлɟкɚɪɫɬɜɟнныɟɫɪɟɞɫɬɜɚнɚимɟноɜɚнилɟкɚɪɫɬɜɟнныɟɫɪɟɞɫɬɜɚоɞноɝонɚимɟноɜɚконцɟнɬɪɚцияɯМɚɪкиɪоɜкɚпɪиɝоɬоɜлɟнныɯкомɛиниɪоɜɚнныɯлɟкɚɪɫɬɜɟнныɯпɪɟпɚɪɚɬоɜинɮɭзионноɝоɜɜɟɞɟɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬɟɯнолоɝияɛиоɬɟɯнолоɝияPharmaceutical Technology and Biotechnologyɞолжнɚɫооɬɜɟɬɫɬɜоɜɚɬьɬɪɟɛоɜɚниямɭɫɬɚноɜпɪиложɟнии 1 Пɪикɚзɚ 751ɜоɞиɬɫяоɮоɪмлɟниɟɫооɬɜɟɬɫɬɜɭющɟйэɬикɟɬкойлɟкɚɪɫɬɜɟнныɟпɪɟпɚɪɚɬыпɚɪɟнɬɟɪɚльноɝоɜɜɟинɮɭзийЭɬикɟɬкɚɛɟломɫиɝнɚльныйцɜɟɬполяэɬикɟɬкɟɞолжныпɪɟɞɭпɪɟɞиɬɟльныɟɋɬɟɪильнонɟɞоɫɬɭпноммɟɫɬɟɬɪɟɛоɜɚнияпомɟщɟниямоɛознɚчɟны XIII ОɎɋлɟкɚɪɫɬɜɟнɫɪɟɞɫɬɜɎɟɞɟɪɚльномзɚконɟ 61-лɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜПɪикɚ 706пɪиложɟнии 15 ?ɌɪɟɛоɜɚнияɪɟжимɚмлɟкɚɪɫɬɜɟнныɯпɪɟпɚɪɚɬоɜɬɚɛлицɟɊɚɫɬɜоɪыинɮɭзийПɪикɚзɚПɟɪɟчиɫлɟннɚяɭɫɬɚнɚɜлиɜɚɟɬɬɪɟɛоɜɚнияɮɚɪмɚцɟɜɬичɟɫкиɯɫɭɛɫɬɚнцийɜɫпомоɝɚɬɟльныɯɜɟщɟɫɬɜɫɬɪɚняɟɬɫяɜɫɟкоɬоɪыɯɫɬоɜɬоɪойɜɚɪиɚнɬизɝоɬоɜлɟнияимɟюɬɫɭщɟɫɬɜɟнныɟɬɪɟɛоɜɚнияɯиɫɯоɞнымкомпонɟнɬɚмɬɟɯнолоɝичɟɫкойɫɯɟмɟизɝоɬоɜлɟнияиɫпользɭɟмомɭоɛоɪɭɞоɜɚниюконɬɪолюкɚчɟɫɬɜɚпɪоɞолжиɬɟльноɫɬикомɛиниɪоɜɚнныɯɮɭзионныɯэкɫɬɟмпоɪɚльноɝоизɝоɬоɜлɟнияɜɚɪиɚнɬɫооɬɜɟɬɫɬɜииɫɬɚɬьɟй 56 ИзɝоɬоɜлɟниɟоɬпɭɫклɟкɚɪɫɬɜɟнныɯпɪɟпɚɪɚɬоɜɎɟɞɟɪɚльноɝозɚконɚ 61-Пɪикɚзɚ 751кɚчɟɫɬɜɟиɫɯоɞныɯкомпонɟнɬоɜизɝоɬоɜлɟнияинɮɭзионныɯɫмɟɫɟйɞолжныиɫпользоɜɚɬьɫяɮɚɪмɚцɟɜɬичɟɫкиɟɫɭɛɫɬɚнцииɜключɟнныɟɫооɬɜɟɬɫɬɜɟнɝоɫɭɞɚɪɫɬɜɟнныйɪɟɟɫɬɪлɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜмɟɞицинɫкоɝоɭɫɬɚноɜлɟнномɪяɞкɟɬɚкжɟɫооɬɜɟɬɫɬɜииɮɚɪмɚкопɟйɫɬɚɬьɟйОɎɋЛɟкɚɪɫɬɜɟнныɟпɚɪɟнɬɟɪɚльноɝоиɫпользоɜɚнияɫоɫɬɚɜɟинɮɭзионныɯɪɚɫɬɜоɪоɜɜɫпомоɝɚɬɟльныɟɜɟщɟɫɬɜɚнɚпɪимɟɪɫɬɚɛилизɚɬоɜоɞɚИнɮɭзионныɟлɟкɚɪɫɬɜɟнɮоɪмыɞолжныизоɬоничнычɟлоɜɟкɚɞолжныɫоɞɟɪжɚɬьконɫɟɪɜɚнɬоɜȼɫɟиɫɯоɞныɟкомпоɞолжнынɚɞлɟжɚщɟɝокɚчɟɫɬɜɚɫооɬɜɟɬɫɬɜоɜɚɬьɬɪɟɛоɜɚниямизɞɚнияПɪинципиɚльнооɬличɚɟɬɫяɬɟɯнолоɝичɟɫкɚяɫɯɟмɚизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯИзɝоɬоɜлɟниɟпɟɪɜомɭɜɚɪиɚнɬɭɜключɚɟɬɜɫɟɫɬɚɞииɬɟɯнолоɝичɟɫкоɝопɪоцɟɫɫɚпоɫɬɚɞийнымконɬɪолɟмпɪиɝоɬоɜлɟнныɯɪɚɫɬɜоɪоɜоɫноɜɚнииɬɪɟɛоɜɚнийПɪикɚзɚПоɞɝоɬоɜиɬɟльнɚяɫɬɚɞияɜключɚɟɬпоɞɝоɬоɜɜоɞыпомɟщɟнияпɟɪɫонɚлɚоɛоɪɭɞоɜɚнияпоɫɭɭкɭпоɪочныɯɫɪɟɞɫɬɜɜɫпомоɝɚɬɟльныɯмɚɬɟɪиɚлоɜɫооɬɜɟɬɫɬɜииПɪикɚзɚми 309 751оɫноɜномɭоɛоɪɭɞоɜɚниюкоɬоɪоɟиɫпользɭɟɬɫяпɟɪɜойɫɬɚɞииɬɟɯнолоɝичɟɫкоɝопɪоцɟɫɫɚоɬноɫяɬɫяɚкɜɚɞиɫɬилляɬоɪыполɭчɟнияɚпиɪоɝɟннойɜоɞыɛɚкɬɟɪициɞныɟмɚшиныпоɫɭɞыɭкɭпоɪочныɯɫɪɟɞɫɬɜɫɭшильныɟшкɚɮызɚɬоɪыɜозɞɭшнойɬɟкɭчимпɚɪомпоɞɞɚɜлɟниɟмИзɝоɬоɜлɟниɟɪɚɫɬɜоɪɚмɚɫɫооɛъɟмнымɬоɞомɜключɚɟɬпɪоɜɟɞɟниɟнɟоɛɯоɞимыɯɪɚɫчɟɬоɜпоɞɝоɬоɜкиɮɚɪмɚцɟɜɬичɟɫкиɯɫɭɛɫɬɚнцийоɬɜɟшиɜɚниɟɜɫпомоɝɚɬɟльныɯɜɟщɟɫɬɜоɬɜɟшиɜɚниɟɪɚɫɬɜоɪиɬɟляоɬмɟɪиɜɚниɟɜоɞыɪɚɫɬɜоɪɟниɟɮɚɪмɚцɟɜɬичɟɫкиɯɫɭɛɫɬɚнцийизоɬониɪɭющиɯɫɬɚɛилизиɪɭющиɯɜɟщɟɫɬɜнɟоɛɯоɞимоɫɬиконɬɪолькɚчɟɫɬɜɚпɪиɝоɬоɜлɟнноɝоɪɚɫɬɜоɪɚɜɬоɪойɫɬɚɞииɬɟɯнолоɝичɟɫкоɝопɪоцɟɫɫɚкɚчɟɫɬɜɟоɛоɪɭɞоɜɚнияиɫпользɭюɬɫяɜɟɫымɟшɚлкиɎильɬɪɚцияɮɚɫоɜкɚɜключɚяɬɜоɪоɜɮлɚконыпоɫлɟɞɭющɟйɭкɭпоɪкоймɚɪкиɪоɜкойпɪоɜɟɞɟниɟмконɬɪолякɚчɟɫɬɜɚɪɚɫɬɜоɪɚИнɮɭзионныɟɪɚɫɬɜоɪыɮильɬɪɭюɬɫяиɫпользоɜɚɮильɬɪоɜɚльныɯмɚɬɟɪиɚлоɜɭɫɬɚноɜокɎильɬɪоɜɚниɟɪɚɫɬɜоɪɚɫочɟɬɚɟɬɫяоɞноɜɪɟмɟннымɪозлиɜомɟɝопоɞɝоɬоɜлɟнныɟɮлɚконыкоɬоɪыɟɭкɭпоɪиɜɚюɬɫяпɪоɛкɚмиИнɬɟɪɜɚлнɚчɚлɚизɝоɬоɜлɟнияинъɟкционноɝоинɮɭзионноɝоɪɚɫɬɜоɪɚɞолжɟнпɪɟɜышɚɬь 3-ОцɟнкɚкɚчɟɫɬɜɚинɮɭзионныɯɪɚɫɬɜоɪоɜпɪоɜоɞиɬɫяоɬɫɭɬɫɬɜиюмɟɯɚничɟɫкиɯɜключɟнийзнɚчɟпоɞлинноɫɬиколичɟɫɬɜɟнномɭɫоɞɟɪжɚлɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜɫоɞɟɪжɚниюизоɬониɪɭɫɬɚɛилизиɪɭющиɯɜɟщɟɫɬɜкɚчɟɫɬɜɟоɛоɪɭɞоɜɚнияɬɪɟɬьɟйɫɬɚɞииɬɟɯнолоɝичɟɫкоɝопɪоцɟɫɫɚиɫпользɭюɬɫяɭɫɬɚноɜкиɮильɬɪɚцииɞозɚɬоɪылɟкɚɪɫɬɜɟнныɯɮоɪмɭɫɬɚноɜкиɪозлиɜɚɪɚɫɬɜоɪоɜɮлɚконыIV. ɋɬɟɪилизɚцияИнɮɭзионныɟɪɚɫɬɜоɪылизɭюɬɫяɫооɬɜɟɬɫɬɜииɬɪɟɛоɜɚниямиɪɟжимɚмɭкɚзɚннымиɬɚɛлицɟ 1 пɪиложɟ 15 Пɪикɚзɚ 751ɞопɭɫкɚɟɬɫяɪɚɫɬɜоɪоɜоɛъɟмомɛолɟɟ 1 лиɬɪɚпоɜɬоɪнɚяинɮɭзионныɯɬɜоɪоɜПɪоцɟɫɫɞолжɟноɛɟɫпɟчиɜɚɬьэɮɮɟкɬиɜноɫɬьɜɫɟɝооɛъɟмɚзɚɝɪɭзкиКонɬɪольпɚɪɚмɟɬɪоɜэɮɮɟкɬиɜноɫɬиɬɟɪмичɟɫкиɯмɟɬоɞоɜоɫɭщɟɫɬɜляɟɬɫяпомощьюконɬɪольноизмɟɪиɬɟльныɯɯимичɟɫкиɯɛиолоɝичɟɫкиɯɬɟɫɬоɜɊɟжимыиɫɯоɞныɯлɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜизɝоɬоɜлɟнныɯинɮɭзионɪɚɫɬɜоɪоɜɬɚкжɟɜɫпомоɝɚɬɟльныɯмɚɬɟɪиɚпоɫɭɞыɪɟɝиɫɬɪиɪɭюɬɫяжɭɪнɚлɟɪɟɝиɫɬɪɚɪɟжимɚиɫɯоɞныɯлɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜизɝоɬоɜлɟнныɯлɟкɚɪɫɬɜɟнныɯпɪɟпɚɪɚɬоɜɜɫпомоɝɚɬɟльныɯмɚɬɟɪиɚлоɜпоɫɭɞыпɪочиɯɬɟɪиɚлоɜчɟɬɜɟɪɬойɫɬɚɞииɬɟɯнолоɝичɟɫкоɝопɪоцɟɫɫɚPharmacy & Pharmacology V. 5 N 4, 2017иɫпользɭюɬɫяɫɬɟɪилизɚɬоɪыɬɟкɭпɚɪомпоɞɞɚɜлɟниɟмɚɜɬоклɚɜыV. КонɬɪолькɚчɟɫɬɜɚКонɬɪолькɚчɟɫɬɜɚɪɚɫɬɜоɪоɜоɫɭщɟɫɬɜляюɬɫяɫооɬɜɟɬɫɬɜииПɪикɚзом 751ɬɪɟɛоɜɚниямиȽоɫɭɞɚɪɫɬɜɟннойɮɚɪмɚкопɟи XIII изɞɚнияиноɝоɞокɭмɟнɬɚконɬɪолякɚчɟɫɬɜɚОцɟнкɚкɚчɟɫɬɜɚинɮɭзионныɯɪɚɫɬɜоɪоɜпоɫлɟпɪоɜоɞиɬɫяоɬɫɭɬɫɬɜиюмɟɯɚничɟɫкиɯɜключɟнийпɪоɜɟɪкɟноминɚльноɝооɛъɟмɚɪозлиɜɟɮлɚконызнɚчɟниюпоɞлинноколичɟɫɬɜɟнномɭɫоɞɟɪжɚниюлɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜоɬклонɟниюноминɚльноɝооɛъɟмɚɫиɪоɜɚнноɫɬиɭкɭпоɪкиɫɬɟɪильноɫɬипиɪоɝɟнноɫоɞɟɪжɚниюɛɚкɬɟɪиɚльныɯэнɞоɬокɫиноɜнɟɫооɬɜɟɬɫɬɜииоɞномɭпɟɪɟчиɫлɟнныɯɬɪɟɛоɜɚнийɪɚɫɬɜоɪыяɜляюɬɫянɟɞоɛɪокɚчɟɫɬɜɟннымиПɪоɞолжиɬɟльноɫɬьпɪиɝоɬоɜлɟнныɯкомɛиниɪоɜɚнныɯлɟкɚɪɫɬɜɟнныɯпɪɟпɚɪɚɬоɜинɮɭзионноɝоɜɜɟɞɟнияɭɫɬɚнɚɜлиɜɚɟɬɫяɫооɬɜɟɬɬɪɟɛоɜɚниямиɭкɚзɚннымиɬɚɛлицɟ 1 пɪиложɟния 15 Пɪикɚзɚ 751ɝоɞноɫɬилɟкɚɪɫɬɜɟнныɯпɪɟпɚɪɚɬоɜɜошɟɞшиɯɬɚɛлицɭɫоɫɬɚɜляюɬинɮɭзийɛолɟɟɫɭɬокɌɚкимоɛɪɚзомɜɚɪиɚнɬэкɫɬɟмпоɪɚльноизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɯɚɪɚкɬɟɪизɭɟɬɫяɫложнойɬɟɯнолоɝичɟɫкойɫɯɟмойɛольшимколичɟɫɬɜомɫɬɚɞийнɟоɛɯоɞимоɫɬьюɫпɟциɚльноɝооɛоɪɭɞоɜɚнияизɝоɬоɜлɟɮильɬɪɚцииɪɚɫɬɜоɪоɜɜыɫокойɬɪɭɞоɟмкоɫɬьюпɪоɞолжиɬɟльноɫɬьюɬɟɯнолоɝичɟɫкоɝонɟɫколькиɯɞɟɬɚльнымконɬɪолɟмкɚчɟɫɬɜɚɬɚкжɟоɬɫɭɬɫɬɜиɟмоɮициɚльɫɬɚɛильноɫɬинɟɫколькиɯɫоɜмɟɫɬнойɬɟɪмичɟɫкойпɚɪомпоɞɞɚɜлɟниɟмɬɟмпɟɪɚɬɭɪɟ 120?ɜозможноɫɬиизɝоɬоɜлɟнияɬɚкиɯинɮɭзионныɯɫмɟɫɟйНɚличиɟцɟлоɝокɪиɬичɟɫкиɯɬочɟкпокɚзыɜɚɟɬонɚльноɫɬьиɫпользоɜɚнияпоɞоɛнойɫɯɟмыизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзиɪɚɫɬɜоɪоɜɚпɬɟкиȼɬоɪойɜɚɪиɚнɬНɟоɛɯоɞимооɬмɟɬиɬьчɬоɜɬоɪойɜɚɪиɚнɬизɝоɬоɜлɟнияпɪоɬиɜоɪɟчиɬɬɪɟɛоɜɚниямзɚпɪɟɬɚизɝоɬоɜлɟнияɚпɬɟкɟзɚɪɟɝиɫɬɪиɪоɜɚнныɯпоɫколькɭпɪɟɞполɚиɫпользоɜɚниɟкɚчɟɫɬɜɟиɫɯоɞныɯкомпонɟнɬоɜизɝоɬоɜлɟнияɮоɪмɜыпɭɫкɚ ? ɪɚɫɬɜоɪыконцɟнɬɪɚɬыɮлɚконɚɯɚмпɭлɚɯлиоɮилизɚɬыɮлɚконɚɯɜоɞɚɜыпɭɫкɚɟмыɟɮɚɪмɚцɟɜɬичɟɫкойпɪомышлɟнноɫɬьюɫлɟɞоɜɚɬɟльнозɚɪɟɝиɫɬɪиɪоɜɚнныɟɝоɫɭɞɚɪɫɬɜɟнномɪɟɟɫɬɪɟнɟɞопоɫɬɚɜкипɪомышлɟнноɝопɪоизɜоɞɫɬɜɚɜозможноиɫпользоɜɚниɟкɚчɟɫɬɜɟиɫɯоɞныɯкомпонɟнɬоɜизɝоɬоɜлɟнныɯɚпɬɟкɟПɪикɚзɭИɫɯоɞныɟкомпонɟнɬыизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜɜɬоɪомɭɜɚɪиɚнɬɭоɬɜɟчɚюɬɬɪɟɛоɜɚниямɞокɭмɟнɬоɜɪɟɝлɚмɟнɬиɪɭющиɯизɝоɬоɜлɟниɟкɚзɚɬɟлямɫɬɟɪильноɫɬиɚпиɪоɝɟнноɫɬиизоɬоничноɫɬиизоɜязкоɫɬиɬɚкжɟимɟюɬɞоɫɬɚɬочныйКɚкɫлɟɞɫɬɜиɟɬɪɟɛɭюɬɫпɟциɚльпоɞɝоɬоɜкиɪɚɫчɟɬоɜɫоɞɟɪжɚнияɮɚɪмɚцɟɜɬичɟɫɭɛɫɬɚнцийɪɚɫɬɜоɪиɬɟлɟйɫɬɚɛилизɚɬоɪоɜɬɚкжɟоɬмɟɪиɜɚнияоɬɜɟшиɜɚнияпɪомышлɟнноɝопɪоизɜоɞɫɬɜɚɜɫɟɝɞɚɞоɫɬɚɬочномɚɫɫоɪɬипɪиɫɭɬɫɬɜɭюɬɚпɬɟкɟопɟɪɚɬиɜноɞоɫɬɚɜлɟныПɪинципиɚльнымоɬличиɟмɜɬоɪоɝоɜɚɪиɚнɬɚизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɬɜоɪоɜяɜляɟɬɫяминимɚльноɟколичɟɫɬɜоɫɬɚɞийɬɟɯнолоɝичɟɫкоɝопɪоцɟɫɫɚПоɞɝоɬоɜиɬɟльнɚяɫɬɚɞияɜключɚɟɬпоɞɝоɬоɜкɭпомɟщɟнияпɟɪɫонɚлɚоɛоɪɭɞоɜɚнияɜɫпомоɝɚɬɟльмɚɬɟɪиɚлоɜИзɝоɬоɜлɟниɟɪɚɫɬɜоɪɚоɫɭщɟɫɬɜляɟɬɫяɫмɟшиɜɚнияоɞноɝонɟɫколькиɯɪɚɫɬɜоɋɬɟɪильноɫɬьиɫɯоɞныɯкомпонɟнɬоɜключɚɟɬнɟоɛɯоɞимоɫɬьиɫпользоɜɚнияпɪоɜɟɞɟнияПоɫколькɭпоɜɬоɪнɚяинɮɭзионныɯɪɚɫɬɜоɪоɜзɚпɪɟщɟнɚПɪикɚзɚМинзɞɪɚɜɚ 26.11.2015 751ɬɟɯнолоɝияизɝоɬоɜлɟнияɞолжныоɛɟɫпɟчиɜɚɬьноɫɬьɝоɬоɜоɝопɪоɞɭкɬɚПɪикɚзɚɪɟкомɟнɞɭɟɬизɝоɬоɜлɟниɟпоɞɜɟɪɝɚющиɯɫяɚɫɟпɬичɟɫкиɯлɚминɚɪномɬокɟɫɬɟɪильноɝоɜозɞɭɯɚизɝоɬоɜлɟнияɬɪɟɛɭɟɬɫяɟмкоɫɬипɪоцɟɫɪɚɫɬɜоɪɟнияпɪоиɫɯоɞяɬзɚɜоɞɫкойɭпɚкоɜкɟɮлɚконɟконɬɟйнɟɪɟКонɬɪолькɚчɟɫɬɜɚИзɝоɬоɜлɟнныɟɜɬоɪомɭɜɚɪиɚнɬɭкомɛиниɪоɜɚнныɟинɮɭзионныɟɬɜоɪыпоɞɜɟɪɝɚюɬɫяконɬɪолюкɚчɟɫɬɜɚɫоɝлɚɫноɬɪɟɛоɜɚниям XIII изɞɚнияПɪикɚзɚминимɚльномɭпɟɪɟчнюпокɚзɚɬɟлɟйоɬɫɭɬɫɬɜиюмɟɯɚничɟɫкиɯɜключɟнийнокɪɚɬнопоɫлɟɫмɟшиɜɚнияпоɞлинноɫɬиколичɟɫɬɜɟнномɭɫоɞɟɪжɚниюлɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜɫɬɟɪильноɫɬипиɪоɝɟнноɫɬиɫоɞɟɪжɚниюɛɚкɬɟɪиɚльныɯэнɞоɬокɫиноɜнɟɫооɬɜɟɬɫɬɜииоɞномɭпɟɪɟчиɫлɟнныɯɬɪɟɛоɜɚнийɪɚɫɬɜоɪыяɜляюɬɫянɟɞоɛɪокɚчɟɫɬɜɟннымиОɛоɪɭɞоɜɚниɟɜɫпомоɝɚɬɟльныɟɌɟɯнолоɝияизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭɪɚɫɬɜоɪоɜɜключɚющɚяоɞноɝонɟɫколькиɯɞоɛɚɜлɟниɟконɬɟйнɟɪɬɜоɪиɬɟлɟмопɪɟɞɟляɟɬминимɚльныйоɛоɪɭɞоɜɚния - кɚмɟɪыɫɬолыпоɬокомɫɬɟɪильноɝоɜозɞɭɯɚпɪоцɟɫɫизɝоɬоɜлɟпɟɪɫонɚлиɫпользɭɟɬɚмпɭлɮлɚконоɜПɪоɞолжиɬɟльноɫɬьизɝоɬоɜлɟинɮɭзионныɯɪɚɫɬɜоɪоɜɜɬоɪомɭɜɚɪиɚнɬɭнɟоɛɯоɞимоɭчиɬыɜɚɬьинɫɬɪɭкциймɟɞицинɫкомɭкоɬоɪыɟɜключɚɬьɬɪɟɛоɜɚнияɬɟмпɟɪɚɬɭɪномɭпɪиɝоɬоɜлɟнныɯɪɚɫɬɜоɪоɜНɚпɪимɟɪȺмокɫиклɚɜпɪиɝоɬоɜлɟнияɪɚɫɬɜоɪɚɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬɟɯнолоɝияɛиоɬɟɯнолоɝияPharmaceutical Technology and Biotechnologyɜнɭɬɪиɜɟнноɝоɜɜɟɞɟнияпɪиɝоɬоɜлɟнныйпользоɜɚниɟм 0,9% ɪɚɫɬɜоɪɚнɚɬɪияможɟɬ 4 чɚɫɚɬɟмпɟɪɚɬɭɪɟ +25? 8 ɬɟмпɟɪɚɬɭɪɟЗɚключɟниɟɌɚкимоɛɪɚзомɜɬоɪойɜɚɪиɚнɬэкɫɬɟмпоɪɚльноɝоизɝоɬоɜлɟниякомɛиниɪоɜɚнныɯинɮɭзионныɯɪɚɫɬɜоɪоɜпɪомышлɟнноɝоизɜоɞɫɬɜɚоɬличɚɟɬɫяпɪоɫɬоɬойɬɟɯнолоɝичɟɫкойɫɯɟмыоɬɫɭɬɫɬɜиɟмɫложныɯɪɚɫчɟɬоɜпоɞɝоɬоɜоɞопоɞɝоɬоɜкɚоɬмɟɪиɜɚниɟоɬɜɟшиɜɚниɟɜɫпомоɝɚɬɟльныɯɜɟщɟɫɬɜɫɬɚɞийɮильɬɪɚцииɜɚɪиɚнɬомконɬɪолякɚчɟɫɬɜɚоɬɫɭɬɫɬɜиɟмɫложноɝооɛоɪɭɞоɜɚЭɬопозɜоляɟɬопɟɪɚɬиɜноɛольшиɯколичɟɫɬɜɚɯизɝоɬɚɜлиɜɚɬькомɛинɚцииинɮɭзионноɝоɜɜɟɞɟнияɚпɬɟкɚɯIntroduction. medicines for infusion administration both as monother--In case of simultaneous administration of two or more medicines in one infusion, the question of the quality of this combination arises [2, 3]. This is due to the tradi-ready solutions) does not allow to ensure the quality, ef, efNowadays in the hospitals providing assistance in stationary conditions, it is traditional to manufacture combined infusion solutions by the nursing staff in pro-technology, each stage of such a scheme is incorrect be-a combined infusion solution, however, the process of its tions is mixing different dosage forms in a single vial or container. Previously, such actions met the de nition of Article 17 of the Federal Law of 22 June 1998 ?On nition of the the At the same time abroad, especially in many countries of Europe, in the United States, and in Australia, the prob-lem of manufacturing quality combined infusion solutions is solved by delegation of powers for extemporaneous manufacturing directly to the pharmacies of medical or-Pharmacy & Pharmacology V. 5 N 4, 2017ganizations [7]. In the Russian Federation, pharmaceutical specialists working in medical organizations providing as- cant contribution to the management of rational pharmacother-Nowadays stationary patients of medical organiza-two components ? medicine (in the form of powder, ly-components ? medicines and solvents. The last option is but mixing different drugs.department conditions is especially acute. According to ow of sterile air, in the treat-The aim of this work was to study and analyze vari-ants of the extemporal manufacture of combined drugs for infusion introduction in hospital pharmacies.Materials and methods. The methodological basis of the study was a systemic approach, which makes it possible to identify the key elements of two different op-medicines for infusion administration. The research uses medical organizations [9, 10, 11]:To choose a rational option, it is necessary to con-the main advantages and disadvantages (Table 1).Table 1 ? Comparative analysis of possible variants of manufacturing combined medicinesEstimated parameterFirst variantSecond variantrders No.1175 and No.751Requirements to premises and per-Requirements for manufacturingSource componentsWater for injectionsRequirements for manufacturingIdenticalTechnology systemAll stages of the technological process ofEquipmentIn accordance with the requirements of owQuality controlFor all indicatorsMinimum of indicatorsMarkingIdenticalStorage conditionsIdenticalcies of medical organizations, the following was es-1. The requirements for preliminary examination of compatibility letters, premises, personnel, manufactur-in accordance with Orders No. 1175 and No. 751n of and pharmaceutical compatibility. The main information ɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬɟɯнолоɝияɛиоɬɟɯнолоɝияPharmaceutical Technology and Biotechnologyregistry www.grls.rosminzdrav.ru, section ?Interaction organization of the operation of the aseptic unit (Para- ows of clear air in The production of multicomponent infusion regimens is carried out on the basis of Order No. 751n, Section VI ?Characteristics of manufacturing dosage forms under aseptic conditions?. These requirements will be the same rst and second versions. Drug manufacturing un-tamination by microorganisms and mechanical particles.nal products with different names or medicinal products ments established in Appendix No. 1 of Order No. 751n. sions? is carried out. The label has a blue signal color in eld on a white background. On the label organization of their storage are indicated in Pharmaco-poea, Federal Law No. 61-FZ, Art. 58 ?Storage of medic-inal products?, Clauses 1-3, Order No. 706n and Annex products?, Table 1 ?Solutions for injection and infusion? of Order No. 751n. The listed documents set general and substances, excipients, drugs and apply to all organiza- rst and second versions of manufacturing cant differences in the requirements for the In accordance with Article 56 ?Manu-tain antimicrobial preservatives. All source components bined infusion mixtures is fundamentally different. Man- rst variant includes all stag-Preparatory stage includes preparation of water, iary materials. In accordance with Orders No. 309 and No. 751n, aqua distillers for the production of pyrogen-free water, bactericidal lamps, dishwashing machines and clo-sures, drying cabinets, sterilizers for air sterilization and owable steam for pressure.The production of a solution by a mass-volumet- l- lter materials and devices. The ltration of the solution is combined with simultaneous lling prepared sterile bottles, which are sealed with sterile stoppers. The interval from the beginning of the manufacture of the injection and infusion solution to ster-As equipment at the third stage of the technological ltration units, dispensers for liquid dosage forms, lling solutions into bottles are used.IV. gimes indicated in Table No. 1 of Appendix No. 15 of Order No. 751n. Do not sterilize solutions larger than ciency of ciency of thermal methods of sterilization Pharmacy & Pharmacology V. 5 N 4, 2017At the fourth stage of the technological process, ster-V. Quality control eld of quality control. Evaluation cation of the nominal volume xity of closure, sterility, pyrogenicity or bacterial endogenous ed in Table No. 1 of Appendix No. 15 of Order No. 751n. The shelf life of drugs not included into Table 1 is not rst version of the extemporal manufacture plex technological scheme, a large number of stages and ltration, sterilization of solutions, high labor-in-to several hours, detailed quality control. It is also char- cial data on the stability of sev-manufacturing such infusion mixtures. The presence of a hospital pharmacy. ed that the sec-manufacturing the drugs, registered in the Russian Feder-ceutical industry, and therefore registered in the public drug register) as the initial components for manufactur-manufacture of sterile drugs for sterility, apyrogenicity, isotonicity, isobaricity and also have a suf cient shelf life. As a consequence, they do not require special prepa-substances, solvents, stabilizers, as well as their meter- cient range of products in the pharmacy, or can be delivered promptly.The principal difference of the second variant of The preparatory stage includes preparation of the by mixing one or more drugs with a solvent. The sterility of the original components of 26.11.2015, No. 751n), the technology and manufac- nished nal ow of sterile air. For manufacturing no capacity is required. Quality control. The combined infusion solutions and quantitative content of drugs, sterility, pyrogenicity inferior.. The technology ow of sterile air. In the manufacturing process, the staff uses . When manufacturing infusion solutions. For example, Amoxiclav powder for the prepa-complex calculations, a number of preparatory oper- ltration and steriliza- ed version of quality control, equip-ment. This gives a possibility to make various combina-quickly and in large quantities.ɎɚɪмɚцияɮɚɪмɚколоɝияɎɚɪмɚцɟɜɬичɟɫкɚяɬɟɯнолоɝияɛиоɬɟɯнолоɝияPharmaceutical Technology and BiotechnologyȻиɛлиоɝɪɚɮичɟɫкийОɬɞɟлɟноɜȺɪɫлɚнɛɟкоɜɚМȿЖЛȿКȺɊɋɌȼȿННЫȿПОЛИПɊȺȽМȺЗИЯПɊȺКɌИКȿȼɊȺЧȺȼɪɚчПɊОȻЛȿМЫȼЗȺИМОȾȿЙɋɌȼИЯЛȿКȺɊɋɌȼКОМȻИНИɊОȼȺННОЙɌȿɊȺПИИНоɜɚяɚпɬɟкɚɋолонининɚМиɯɚйлоɜɚɊоɫɬоɜɚМиɯɚйлоɜлɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜ ? ɫоɫɬояниɟпɪоɛлɟмы // ПɟɪɫпɟкɬиɜыɚпɬɟкɬɟзȺпɬɟчнɚяɫɟɬьɊоɫɫииȼɫɟɪоɫɫконɮȿɝоɪоɜɚНɟɜолинɚИЗȽОɌОȼЛȿНИȿЛȿКȺɊɋɌȼȿННЫɏɎОɊМПɊОȻЛȿМЫɌɊȿȻɍЮЩИȿПɊȺȼОȼОȽОȼɟɫɬникɊоɫзɞɪɚɜнɚɞзоɪɚОɊȽȺНИЗȺЦИЯɊȺȻОɌЫɋОɋɌȺȼȿПɊОɎИЛȺКɌИЧȿɋКОȽОПОЛОЖИɌȿЛЬНЫȿȺɋПȿКɌЫɋЛОЖНОɋɌИȾȿЯɌȿЛЬНОɋɌИЗɚмɟɫɬиɬɟльɝлɚɜноɝоɜɪɚчɚ 2011. Ɏɟɞɟɪɚльныйзɚкон 12.04.2010 лɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜ?http://pravo.gov.ru/?://HYPERLINK ?http://pravo.gov.ru/?pravoHYPERLINK ?http://pravo.gov.ru/?.HYPERLINK ?http://pravo.gov.ru/?govHYPERLINK ?http://pravo.gov.ru/?.HYPERLINK ?http://pravo.gov.ɞɚɬɚЯɝɭɞинɚПɪоцɟнкоМиɫикоɜɚОɋОȻȿННОɋɌИɎɍНКЦИОНИɊОȼȺНИЯȻОЛЬНИЧНЫɏɋɌɊȺНȺɏȿȼɊОПȿЙɋКОȽОЗȺɊɍȻȿЖНЫЙɎОɊМИɊОȼȺНИЯКЛИНИЧȿɋКОЙɎȺɊМȺЦИИЛɟкɚɪɫɬɜɟнноɟоɛɟɫпɟчɟниɟɊоɫɫии 2011. Proctor A.E., Rowe E. Outside the hood. Pharmacy Time. 2014. Vol.1. P. 48-51.ПɪикɚзМинзɞɪɚɜɚ 21 окɬɭɬɜɟɪжɞɟнииинɫɬɪɭкцииɫɚниɬɚɪномɭɚпɬɟчныɯɚпɬɟкизмɟнɟниями 24 ɚпɪɟля 2003 gov.ru/?://HYPERLINK ?http://pravo.gov.ru/?pravoHYPERLINK ?http://pravo.gov.ru/?.HYPERLINK ?http://pravo.gov.ru/?govHYPERLINK ?http://pravo.gov.ru/?.HYPERLINK ?http://pravo.gov.ru/?ru (ɞɚɬɚПɪикɚзМинзɞɪɚɜɫоцɪɚзɜиɬия 23.08.2010 ɪɟɞ 28.12.2010) ?ɭɬɜɟɪжɞɟниилɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜ? URL: httpHYPERLINK ?http://pravo.gov.ru/?://HYPERLINK ?http://pravo.gov.ru/?pravoHYPERLINK ?http://pravo.gov.ru/?.HYPERLINK ?http://pravo.gov.ru/?govHYPERLINK ?http://pravo.gov.ru/?.HYPERLINK ?http://pravo.gov.ru/?ru (ɞɚɬɚПɪикɚзМинзɞɪɚɜɚ 26.11.2015 751ɭɬɜɟɪжɞɟнииизɝоɬоɜлɟнияоɬпɭɫкɚлɟкɚɪɫɬɜɟнныɯпɪɟпɚɪɚɬоɜмɟɞицинɫкоɝоɚпɬɟчнымиинɞиɜиɞɭɚльнымипɪɟɞпɪинимɚɬɟлямиɮɚɪмɚцɟɜɬичɟɫкɭюɞɟяɬɟльноɫɬьpravo.gov.ru/?://HYPERLINK ?http://pravo.gov.ru/?pravoHYPERLINK ?http://pravo.gov.ru/?.HYPERLINK ?http://pravo.gov.ru/?govHYPERLINK ?http://pravo.gov.ru/?.HYPERLINK ?http://pravo.gov.ru/?ru (ɞɚɬɚReferencesSychev D.A., Otdelenov V.A., Danilina K., Anikin G., Arslanbekova S. MEZHLEKARSTVENNYYE VZAI-MODEYSTVIYA I POLIPRAGMAZIYA V PRAKTIKE VRACHA [Inter-drug interactions and polypharmacy VrachrachDoctor]. 2013. N 5. Ɋ. 5?8. (In Russ.)2. Zamoschina Ɍ.Ⱥ. PROBLEMY VZAIMODEYSTVIYA LEKARSTV PRI KOMBINIROVANNOY TERAPII [PROBLEMS OF INTERACTION OF DRUGS IN COMBINATION THERAPY]. THERAPY]. New phar-3-1. P. 63-69. (In Russ.)Soloninina A.V., Mikhailova N.V., Rostova N.B., Mikhailov V.G. Obrashcheniye lekarstvennykh sredstv v LPU ? sostoyaniye, problemy, puti resheniya [Treatment of drugs in the health facility - the state, problems, ways of solving]. Perspektivy razvitiya aptek LPU: tez.dokl. Aptechnaya set? Rossii: XIII Vseross. konf. [Prospects of development of pharmacies of medical institutions]. 2008. P. 57?64. (In Russ.)Egorova S.N., Nevolin E.V. APTECHNOYe IZGOTOVLENIYe LEKARSTVENNYKH FORM: PROBLEMY, TREBUYUSHCHIYe PRAVOVOGO RESHENIYA [Pharmaceutical manufacture of dosage forms: problems Vestnik Roszdravnadzoraestnik RoszdravnadzoraBulletin of Roszdravnadzor]. 2013. No.6. P. 36?38. (In Russ.)Ilyin O.M. ORGANIZATSIYA RABOTY APTEKI V SOSTAVE LECHEBNO-PROFILAKTICHESKOGO UCHREZHDENIYA: POLOZHITEL?NYYe ASPEKTY I SLOZHNOSTI OBESPECHENIYA DEYATEL?NOS-TI [Organization of pharmacy work in the medical-prophylactic establishment: positive aspects and dif culties in Zamestitel? glavnogo vracha glavnogo vrachaDeputy Chief Physician]. 2011. No.12 (67). P. 72-76 (In Russ.) 72-76 (In Russ.)nykh sredstv? [?On the circulation of medicines?] URL: http://pravo.gov.ru (access data: 25.04.2017). (In Russ.)Yagudina R.I., Protsenko M.V., Misikov B.B. OSOBENNOSTI FUNKTSIONIROVANIYA BOL?NICHNYKH APTEK V STRANAKH YEVROPEYSKOGO SOYUZA. ZARUBEZHNYY OPYT FORMIROVANIYA SOVREMENNOY KLINICHESKOY FARMATSII [Features of the functioning of hospital pharmacies in the Pharmacy & Pharmacology V. 5 N 4, 2017 5 N 4, 2017Pharmaceutical provision in Russia]. 2011. N 2. P. 72?81. (In Russ.)Proctor A.E., Rowe E. Outside the hood. Pharmacy Time. 2014.Vol. 1. P. 48?51. 48?51.October. 1997 N 309]. ?Ob utverzhdenii instruktsii po sanitarnomu rezhimu aptechnykh organizatsiy (aptek)?[?On approval of instructions on the sanitary regime of pharmacy organizations (pharmacies)?] (s izmeneniyami ot 24 aprelya 2003 g.) [(as amended on April 24, 2003)] URL: http://pravo.gov.ru (access data: 25.04.2017) (In Russ.).ru (access data: 25.04.2017) (In Russ.)eration of 26.11.2015 751 751lekarstvennykh sredstv? [?On the approval of the rules for manufacturing and dispensing medicinal products for medical use by pharmacy organizations, individual entrepreneurs licensed for pharmaceutical activities?] URL: http://pravo.gov.ru (access data: 25.04.2017). (In Russ.)Prikaz Minzdrava RF ot 26.11.2015 g. 751n [On order of the Ministry of Health and Social Development of 706n]. ?Ob utverzhdenii pravil izgotovleniya i otpuska lekarstvennykh preparatov dlya meditsinskogo primeneniya aptechnymi organizatsiyami, individual?nymi predprinimatelyami, ganizatsiyami, individual?nymi predprinimatelyami, of Medicinal Products?] URL: http://pravo.gov.ru (access data: 25.04.2017) (In Russ.) ict of interest ict of interest. - Doctor of Sciences (Pharmacy), Professor, Head of the Department of Phar-macy of Irkutsk State Medical Academy of Postgraduate Education - a branch of the Russian Medical Academy of Continuing Vocational Education of the Ministry of Health of the Russian Federation. Research interests: system research in the eld of improving drug supply in medical organizations that provide assistance in sta-tionary conditions, improving approaches to the system of continuing education of pharmacists. ORCID: orcid.org/0000-0003-4472-4003. E-mail: kovalskaya_gn@ - assistant cal Academy of Postgraduate Education - a branch of the Russian Medical Academy of Continuing Vocation-Federation. Research interests: the technology of sterile dosage forms for infusion, the extemporal production of sterile medicines, the introduction of the GMP standard. ORCID: orcid.org/0000-0002-8568-1372. E-mail: kat-КонɮликɬинɬɟɪɟɫоɜȺɜɬоɪызɚяɜляюɬоɬɫɭɬɫɬɜииконɮликɬɚинɬɟɪɟɫоɜȺɜɬоɪыКоɜɚльɫкɚяȽɚлинɚНиколɚɟɜнɚɞокɬоɪɮɚɪмɚцɟɜɬичɟɫкиɯнɚɭкпɪоɮɟɫɫоɪзɚɜɟɞɭющийкɚɮɟɞɪойɮɚɪмɚцииИɪкɭɬɫкойɝоɫɭɞɚɪɫɬɜɟнноймɟɞицинɫкойɚкɚɞɟмиипоɫлɟɞипломноɝооɛɪɚзоɜɚния ? ɊоɫɫийɫкойɎȽȻɍɊоɫɫийɫкɚямɟɞицинɫкɚяɚкɚɞɟмияпɪоɮɟɫɫионɚльноɝооɛɪɚзоɜɚнияМиниɫɬɟɪɫɬɜɚзɞɪɚɜооɯɪɚнɟнияɊоɫɫийɫкойɎɟɞɟɪɚцииОɛлɚɫɬьнɚɭчныɯинɬɟɪɟɫоɜɫиɫɬɟмныɟиɫɫлɟɞоɜɚнияоɛлɚɫɬиɫоɜɟɪшɟнɫɬɜоɜɚниялɟкɚɪоɛɟɫпɟчɟниямɟɞицинɫкиɯокɚзыɜɚющиɯпомощьɫɬɚционɚɪныɯɭɫлоɜияɯɜɟɪшɟнɫɬɜоɜɚниɟпоɞɯоɞоɜɫиɫɬɟмɟоɛɪɚзоɜɚнияɮɚɪмɚции. ORCID: orcid.org/0000-0003-4472-4003. E-mail: kovalskaya_gn@МиɯɚлɟɜичȿкɚɬɟɪинɚНиколɚɟɜнɚкɚɮɟɞɪыɮɚɪмɚцииИɪкɭɬɫкойɝоɫɭɞɚɪɫɬɜɟнмɟɞицинɫкойɚкɚɞɟмиипоɫлɟɞипломноɝооɛɪɚзоɜɚния ? ɮилиɚлɚɊоɫɫийɫкойɎȽȻɍɊоɫɫийɫкɚямɟɞицинɫкɚяɚкɚɞɟмияпɪоɮɟɫɫионɚльоɛɪɚзоɜɚнияМиниɫɬɟɪɫɬɜɚзɞɪɚɜооɯɪɚнɟнияɊоɫɫийɫкойɎɟɞɟɪɚцииОɛлɚɫɬьнɚɭчныɯинɬɟɪɟɫоɜɬɟɯнолоɝиялɟкɚɪɫɬɜɟнныɯɮоɪмɮɭзионноɝоɜɜɟɞɟнияэкɫɬɟмпоɪɚльноɟизɝоɬоɜлɟниɟлɟкɚɪɫɬɜɟнныɯɜнɟɞɪɟниɟɫɬɚнɞɚɪɬɚ GMP. ORCID: orcid.org/0000-0002-8568-ПоɫɬɭпилɚɪɟɞɚкциюОɬпɪɚɜлɟнɚɞоɪɚɛоɬкɭПɪиняɬɚпɟчɚɬи
×

About the authors

G. N. Kovalskaya

Irkutsk State Medical Academy of Postgraduate Education – a branch of the Russian Medical Academy of Continuing Vocational Education

Email: kovalskaya_gn@mail.ru

E. N. Mikhalevich

Irkutsk State Medical Academy of Postgraduate Education – a branch of the Russian Medical Academy of Continuing Vocational Education

Email: katterina24@list.ru

References

  1. Сычев Д.А., Отделенов В., Данилина К., Аникин Г., Арсланбекова С. МЕЖЛЕКАРСТВЕННЫЕ ВЗАИМОДЕЙСТВИЯ И ПОЛИПРАГМАЗИЯ В ПРАКТИКЕ ВРАЧА // Врач. 2013. № 5. С. 5–9.
  2. Замощина Т.А. ПРОБЛЕМЫ ВЗАИМОДЕЙСТВИЯ ЛЕКАРСТВ ПРИ КОМБИНИРОВАННОЙ ТЕРАПИИ // Новая аптека. 2012. № 3–1. С. 63-69.
  3. Солонинина А.В., Михайлова В.Н., Ростова Н.Б., Михайлов В.Г. Обращение лекарственных средств в ЛПУ – состояние, проблемы, пути решения // Перспективы развития аптек ЛПУ: тез. докл. Аптечная сеть России: XIII Всеросс. конф. М, 2008. С. 57–64.
  4. Егорова С.Н., Неволина Е.В. АПТЕЧНОЕ ИЗГОТОВЛЕНИЕ ЛЕКАРСТВЕННЫХ ФОРМ: ПРОБЛЕМЫ, ТРЕБУЮЩИЕ ПРАВОВОГО РЕШЕНИЯ // Вестник Росздравнадзора. 2013. № 6. С. 36-38.
  5. Ильин О.М. ОРГАНИЗАЦИЯ РАБОТЫ АПТЕКИ В СОСТАВЕ ЛЕЧЕБНО-ПРОФИЛАКТИЧЕСКОГО УЧРЕЖДЕНИЯ: ПОЛОЖИТЕЛЬНЫЕ АСПЕКТЫ И СЛОЖНОСТИ ОБЕСПЕЧЕНИЯ ДЕЯТЕЛЬНОСТИ // Заместитель главного врача. 2011. № 12(67). С. 72-76
  6. Федеральный закон от 12.04.2010 №61-ФЗ «Об обращении лекарственных средств» URL: httpHYPERLINK «http://pravo.gov.ru/»://HYPERLINK «http://pravo.gov.ru/»pravoHYPERLINK «http://pravo.gov.ru/». HYPERLINK «http://pravo.gov.ru/»govHYPERLINK «http://pravo.gov.ru/».HYPERLINK «http://pravo.gov.ru/»ru (дата обращения 25.04.2017 г.)
  7. Ягудина Р.И., Проценко М.В., Мисикова Б.Б. ОСОБЕННОСТИ ФУНКЦИОНИРОВАНИЯ БОЛЬНИЧНЫХ АПТЕК В СТРАНАХ ЕВРОПЕЙСКОГО СОЮЗА. ЗАРУБЕЖНЫЙ ОПЫТ ФОРМИРОВАНИЯ СОВРЕМЕННОЙ КЛИНИЧЕСКОЙ ФАРМАЦИИ // Лекарственное обеспечение в России. 2011. № 2. С. 72–81.
  8. Proctor A.E., Rowe E. Outside the hood. Pharmacy Time. 2014. Vol.1. P. 48-51.
  9. Приказ Минздрава РФ от 21 окт. 1997 г. N 309 «Об утверждении инструкции по санитарному режиму аптечных организаций (аптек)» (с изменениями от 24 апреля 2003 г.) URL: httpHYPERLINK «http://pravo.gov.ru/»://HYPERLINK «http://pravo.gov.ru/»pravoHYPERLINK «http://pravo.gov.ru/».HYPERLINK «http://pravo.gov.ru/»govHYPERLINK «http://pravo.gov.ru/».HYPERLINK «http://pravo.gov.ru/»ru (дата обращения 25.04.2017 г.)
  10. Приказ Минздравсоцразвития РФ от 23.08.2010 №706н (ред. от 28.12.2010) «Об утверждении Правил хранения лекарственных средств» URL: httpHYPERLINK «http://pravo.gov.ru/»://HYPERLINK «http:// pravo.gov.ru/»pravoHYPERLINK «http://pravo.gov.ru/».HYPERLINK «http://pravo.gov.ru/»govHYPERLINK «http://pravo.gov.ru/».HYPERLINK «http://pravo.gov.ru/»ru (дата обращения 25.04.2017 г.)
  11. Приказ Минздрава РФ от 26.11.2015 г. № 751н «Об утверждении правил изготовления и отпуска лекарственных препаратов для медицинского применения аптечными организациями, индивидуальными предпринимателями, имеющими лицензию на фармацевтическую деятельность» URL: httpHYPERLINK «http:// pravo.gov.ru/»://HYPERLINK «http://pravo.gov.ru/»pravoHYPERLINK «http://pravo.gov.ru/».HYPERLINK «http://pravo.gov.ru/»govHYPERLINK «http://pravo.gov.ru/».HYPERLINK «http://pravo.gov.ru/»ru (дата обращения 25.04.2017 г.)

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Kovalskaya G.N., Mikhalevich E.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 67428 от 13.10.2016. 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies